personal information jean-michel dogné · curriculum vitae personal information jean-michel dogné...

Curriculum vitae

PERSONAL INFORMATION Jean-Michel Dogné

WORK EXPERIENCE

July 1996–November 2000 PhD Student in pharmaceutical sciencesUniversity of Liège (Belgium)

PH.D. Thesis Drug design and developpment

December 2000–September2005

PhD, Assistant (Professor)University of Liège (Belgium)

Drug design, drug developpment

January 2006–Present Expert in pharmacovigilanceFederal Agency for Medicines and Health Products (Belgium)

Pharmacovigilance, Drug safety

May 2006–July 2012 Belgian delegate at the PhVWP of the EMAFederal Agency for Medicines and Health Products (Belgium)


July 2012–Present Belgian member of the PRAC of the EMAFederal Agency for Medicines and Health Products (Belgium)


September 2005–Present Full ProfessorUniversity of Namur (Belgium)

Regulatory medicines, Drug developpment, Pharmacology (non clinical & clinical), Thrombosis & Hemostasis research, Nanotoxicology, Pharmacovigilance, Drug safety, Vaccine safety

EDUCATION AND TRAINING

September 1991–July 1996 Pharm.D.University of Liège (Belgium)

September 1996–November2000

Ph.D in pharmaceutical sciencesUniversity of Liège (Belgium)

ADDITIONAL INFORMATION

Expertise Drug Safety and Regulatory Medicines

• Vaccine safety (pre and post-marketing)

• Safety of medicines for selected systems/organ classes (Hematological and cardiovascular ADRs, medicines affecting the QT interval)

• Risk management plans, risk minimisation measures (and assessment of the effectiveness of the risk minimisation measures)

• Signal detection and signal management

• Data mining

24/1/20 © European Union, 2002-2019 | http://europass.cedefop.europa.eu / 31

Curriculum vitae Jean-Michel Dogné

• Post-authorization safety studies (PASS)

• Quality in pharmacovigilance

• Pharmacogenomics and pharmacogenetics of medicines

Other expertises:

• Drug development

• Non clinical and clinical pharmacology and toxicology (inc. nanotoxicology)

• Research expertise: development and monitoring of the antiplatelet and anticoagulant agents, hemocompatibility of biomaterials, nanotoxicology

Publications 1. Published works, as an author, a co-author or an editor

2020

Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogne J-M et al. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. Journal of Thrombosis and Thrombolysis. 2020. https://doi.org/10.1007/s11239-019-02030-5

2019

Morimont L, Evrard J, Bouvy C, Dogne J-M, Douxfils J. Assessment of Second and Third Generation Oral Contraceptives APC Resistance by a Newly Validated ETP-Based APC Resistance Assay: A Pilot Study. 2019. Poster présenté à 27TH BSTH Annual Meeting, .

Morimont L, Evrard J, Bouvy C, Dogne J-M, Douxfils J. Assessment of thrombomodulin resistance in women using second generation, third generation and progestin-only contraceptives. 2019. Poster présenté à 27TH BSTH Annual Meeting, .

Morimont L, Bouvy C, Delvigne A-S, Dogne J-M, Douxfils J. Proposition of a new scale for the harmonization and normalization of the nAPCsr: a scientific and regulatory need for clinical studies comparison. 2019. Poster présenté à 27TH BSTH Annual Meeting, .

Morimont L, Bouvy C, Delvigne A-S, Dogne J-M, Douxfils J. Validation of an original ETP-based APC resistance assay for the evaluation of prothrombotic states. 2019. Poster présenté à 27TH BSTH Annual Meeting, .

Douxfils J, Gheldof D, Dogné J-M, Inventeurs. METHOD FOR DIAGNOSING HAEMOSTASIS DISORDERS USING ACTIVATED CHARCOAL. G01N 33/ 86 A I. 2019 août 15.

Morimont L, Evrard J, Bouvy C, Dogne J-M, Douxfils J. Assessment of Second and Third Generation Oral Contraceptives APC Resistance by a Newly Validated ETP-Based APC Resistance Assay: A Pilot Study. 2019. Poster présenté à ISTH 2019 : The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australie.

Morimont L, Evrard J, Bouvy C, Dogne J-M, Douxfils J. Assessment of Second and Third Generation Oral Contraceptives APC Resistance by a Newly Validated ETP-Based APC Resistance Assay: A Pilot Study. Dans ISTH 2019 XXVII Congress - Final Program . 2019

Morimont L, Evrard J, Bouvy C, Dogne J-M, Douxfils J. Assessment of thrombomodulin resistance in women using second generation, third generation and progestin-only contraceptives. 2019. Poster présenté à ISTH 2019 : The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australie.

Morimont L, Evrard J, Bouvy C, Dogne J-M, Douxfils J. Assessment of thrombomodulin resistance in women using second generation, third generation and progestin-only contraceptives. Dans ISTH 2019 XXVII Congress - Final Program. 2019

Morimont L, Bouvy C, Dogne J-M, Douxfils J. Data interpretation of the ETP-based APC resistance assay and the concept of nAPCsr10, an improved nAPCsr. 2019.

Morimont L, Bouvy C, Dogne J-M, Douxfils J. Data interpretation of the ETP-based APC resistance assay and the concept of nAPCsr10, an improved nAPCsr. Dans ISTH 2019 XXVII Congress - Final Program. 2019

Morimont L, Bouvy C, Dogne J-M, Douxfils J. Validation of an original ETP-based APC resistance assay for the evaluation of prothrombotic states. 2019. Poster présenté à ISTH 2019 : The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australie.

Morimont L, Bouvy C, Dogne J-M, Douxfils J. Validation of an original ETP-based APC resistance assay for the evaluation of prothrombotic states. Dans ISTH 2019 XXVII Congress - Final Program. 2019

Gheldof D, Delvigne A-S, Bouvy C, Douxfils J, Dogne J-M. Assessment of the Efficacy and the Impact



of the Rapid, Practical and Ergonomic DOAC & Platelets Filter Device on Thrombin Generation Assay. 2019. Poster présenté à ISTH 2019 : The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australie.

Gheldof D, Delvigne A-S, Bouvy C, Douxfils J, Dogne J-M. Assessment of the Efficacy and the Impactof the Rapid, Practical and Ergonomic DOAC & Platelets Filter Device on Thrombin Generation Assay. Dans Research and Practice in Thrombosis and Haemostasis. S1 Ed. Vol 3. 2019. p. 144 - 145. (Research and Practice in Thrombosis and Haemostasis). https://doi.org/10.1002/rth2.12229

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J et al. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles. Medicine (Mumbai): analytical reviews of general medicine, neurology, psychiatry, dermatology and pediatrics . 2019 juil. 1;98(27):e16164. https://doi.org/10.1097/MD.0000000000016164

Gheldof D, Delvigne A-S, Bouvy C, Douxfils J, Dogne J-M. A Rapid, Practical and Ergonomic Device to Prepare Plasma Sample Free of Platelets and Direct Oral Anticoagulant for Routine Hemostasis Tests. 2019. Poster présenté à ISTH 2019 : The XXVII Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australie. https://doi.org/10.1002/rth2.12229

Gheldof D, Delvigne A-S, Bouvy C, Douxfils J, Dogne J-M. A Rapid, Practical and Ergonomic Device to Prepare Plasma Sample Free of Platelets and Direct Oral Anticoagulant for Routine Hemostasis Tests. Dans Research and Practice in Thrombosis and Haemostasis. 1 Ed. Vol 3. Wiley. 2019. p. 139 - 140. (Research and Practice in Thrombosis and Haemostasis). https://doi.org/10.1002/rth2.12229

Haguet H, Mullier F, Graux C, Dogne J-M, Douxfils J. An updated meta-analysis of the risks of arterial and venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukemia. 2019. Poster présenté à 24th Congress of EHA, Amsterdam, Pays-Bas.

Fichera O, Alpan L, Laloy J, Tabarrant T, Uhrner U, Ye Q et al. Characterization of water-based paints containing titanium dioxide or carbon black as manufactured nanomaterials before and after atomization. Applied Nanoscience . 2019 juin 1;9(4):515-528. https://doi.org/10.1007/s13204-019-01030-4

Evrard J, Siriez R, Morimont L, Thémans P, Laloy J, Bouvy C et al. Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. International Journal of Laboratory Hematology. 2019 juin 1;41(3):316-324. https://doi.org/10.1111/ijlh.12975

Siriez R, Evrard J, Dogne J-M, Pochet L, Bouvy C, Lessire S et al.. Impact of betrixaban on chromogenic anti-Xa assays - Methodologies improvements. 2019.

Siriez R, Evrard J, Dogne J-M, Pochet L, Bouvy C, Lessire S et al. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. International Journal of Laboratory Hematology. 2019 avr. 1;41(2):250-261. https://doi.org/10.1111/ijlh.12963

Wannez A, Devalet B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Extracellular Vesicles in Red Blood Cell Concentrates: An Overview. Transfusion Medicine Reviews. 2019 avr. 1;33(2):125-130. https://doi.org/10.1016/j.tmrv.2019.02.002

Palazzo C, Laloy J, Delvigne AS, Nys G, Fillet M, Dogne JM et al. Development of injectable liposomes and drug-in-cyclodextrin-in-liposome formulations encapsulating estetrol to prevent cerebral ischemia of premature babies. European Journal of Pharmaceutical Sciences. 2019 janv. 15;127:52-59. https://doi.org/10.1016/j.ejps.2018.10.006

Douxfils J, Morimont L, Bouvy C, de Saint-Hubert M, Devalet B, Devroye C et al. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. Journal of thrombosis and haemostasis : JTH. 2019 janv. 1;17(8):1273-1287. https://doi.org/10.1111/jth.14470

Haguet H, Graux C, Dogne J-M, Mullier F, Douxfils J. In vitro investigations of the effect of BCR-ABL Tyrosine Kinase Inhibitors on endothelial cell viability. 2019. Poster présenté à 34th BHS general annual meeting, La Hulpe, Belgique.

Siriez R, Evrard J, Laloy J, Dogne J-M, Douxfils J. An ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method for the quantification of edoxaban: The importanceto measure active metabolite. 2019.

Siriez R, Evrard J, Laloy J, Dogne J-M, Douxfils J. An ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method for the quantification of edoxaban: The importanceto measure active metabolite. Dans BSTH Abstract Book 2019*. 2019

Siriez R, Evrard J, Dogne J-M, Mullier F, Douxfils J. Comparison of the impact of DOACs on hemostasis diagnostic tests. Dans Comparison of the impact of DOACs on hemostasis diagnostic tests. 2019



Siriez R, Evrard J, Dogne J-M, Pochet L, Bouvy C, Lessire S et al.. Impact of betrixaban on chromogenic anti-Xa assays: Methodologies improvements. 2019.

Douxfils J, Morimont L, Delvigne A-S, Devel P, Masereel B, Haguet H et al. Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. Clinical Chemistry and Laboratory Medicine. 2019. https://doi.org/10.1515/cclm-2019-0471

2018

Minet V, Evrard J, Vancraeynest C, Dogné JM, Mullier F, Pochet L. Development and validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of serotonin and thromboxane B2 from activated platelets. International Journal of Laboratory Hematology. 2018 déc. 1;40(6):663-671. https://doi.org/10.1111/ijlh.12901

Sennesael A-L, Larock A-S, Douxfils J, Elens L, Stillemans G, Wiesen M et al. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis journal. 2018 nov. 12;16(1):28. 28. https://doi.org/10.1186/s12959-018-0183-3

Siriez R, Evrard J, Dogne J-M, Pochet L, Gheldof D, Chatelain B et al.. Betrixaban: Impact on routine and specific coagulation assays - Practical laboratory guidance. 2018.

Vatzaki E, Straus S, Dogne JM, Garcia Burgos J, Girard T, Martelletti P. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: Overview from European Medicines Agency and European Headache Federation. Journal of Headache and Pain. 2018 août 14;19(1). 6. https://doi.org/10.1186/s10194-018-0898-3

Haguet H, Douxfils J, Chatelain C, GRAUX C, Mullier F, Dogne J-M. In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions. 2018. Poster présenté à 64 th Annual International Society on Thrombosis and Haemostasis SSC meeting, Dublin, Irlande.

Siriez R, Chatelain B, Devel P, Dogne J-M, Douxfils J, Mullier F et al.. Betrixaban: Impact on routine and specific coagulation assays -Practical laboratory guidance. 2018. Poster présenté à 64 th Annual International Society on Thrombosis and Haemostasis SSC meeting, Dublin, Irlande.

Siriez R, Evrard J, Dogne J-M, Pochet L, Gheldof D, Chatelain B et al. Betrixaban: Impact on routine and specific coagulation assays - A practical laboratory guide. Dans JTH - Journal of thrombosis and haemostasis: Research and Practice in thrombosis and haemostasis. Issue S1 Ed. Vol Volume 2. 2018. PB364

Evrard J, Siriez R, Bouvy C, Laloy J, Mullier F, Dogne J-M et al. Clot waveform analysis: Determination of optimal wavelength to assess the fibrin coagulation process. Dans JTH-Journal of Thrombosis and haemostasis: Research and practice of thrombosis and haemostasis. issue S1 Ed. Vol 2. 2018. PB385

Evrard J, Siriez R, Themans P, Laloy J, Mullier F, Dogne J-M et al. Clot waveform analysis for measuring and quantifying fibrin clot formation. Dans JTH - Journal of thrombosis and haemostasis: Research and pratice in thrombosis and haemostasis. issue S1 Ed. Vol 2. 2018. PB582

Haguet H, Douxfils J, Chatelain C, GRAUX C, Mullier F, Dogne J-M. In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions. Dans Special Issue: Abstracts of the 64th Annual Meeting of the Scientific Standardization Committee of the International Society on Thrombosis and Haemostasis, July 18–21, 2018. 2018. p. 242. PB497. (Research and Practice in Thrombosis and Haemostasis; S1).

Siriez R, Evrard J, Dogne J-M, Pochet L, Gheldof D, Chatelain B et al. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide. Thrombosis and Haemostasis. 2018 juil. 1;118(7):1203-1214. https://doi.org/10.1055/s-0038-1657772

Postigo R, Brosch S, Slattery J, van Haren A, Dogné JM, Kurz X et al. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Safety. 2018 juil. 1;41(7):665-675. https://doi.org/10.1007/s40264-018-0647-1

Sennesael AL, Larock AS, Devalet B, Mathieux V, Verschuren F, Muschart X et al. Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. British Journal of Clinical Pharmacology. 2018 juil. 1;84(7):1544-1556. https://doi.org/10.1111/bcp.13580

Kälviäinen R, Straus S, Dogne JM, Bakchine S, Haas M. Reducing valproate use in women with epilepsy. The Lancet Neurology. 2018 juil. 1;17(7):580-581. https://doi.org/10.1016/S1474-4422(18)30172-8

Wannez A, Bouvy C, Devalet B, Jacqmin H, Chatelain B, Chatelain C et al.. Involvement of leucocyte derived extracellular vesicles in the procoagulant state found in paroxysmal nocturnal hemoglobinuria-related condition. 2018. Poster présenté à 23nd European Hematology Association, Stockholm,



Suède.

Siriez R, Chatelain B, Devel P, Dogne J-M, Douxfils J, Mullier F et al.. Betrixaban: Impact on routine and specific coagulation assays -Practical laboratory guidance. 2018. Poster présenté à 31st International symposium on technical innovations in laboratory hematology, Bruxelles, Belgique.

Bouvy C, Laloy J, Chatelain C, Dogne J-M. Le transfert de résistances aux agents anticancéreux par les vésicules extracellulaires: une nouvelle vision du développement des chimiorésistances. OncoHemato. 2018 avr.;12(2):18-22.

Siriez R, Evrard J, Dogne J-M, Mullier F, Pochet L, Gheldof D et al.. Betrixaban: Impact on routine andspecific coagulation assays - Practical laboratory guidance. 2018. Poster présenté à 33rd General Annual Meeting Belgian Hematology Society, La Hulpe, Belgique.

Douxfils J, Ageno W, Samama C-M, Lessire S, Ten Cate H, Verhamme P et al. Laboratory Testing In Patients Treated With Direct Oral Anticoagulants: A Practical Guide For Clinicians. Journal of thrombosis and haemostasis : JTH. 2018 févr. 1;16(2):209-219. https://doi.org/10.1111/jth.13912

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J et al. Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Blood transfusion = Trasfusione del sangue. 2018 févr.;16(2):163-172. https://doi.org/10.2450/2017.0230-16

Haguet H, Douxfils J, Mullier F, Dogne J-M. BJH congress highlights: Highlitghs in hemostasis. Belgian Journal of Hematology Volume. 2018 févr.;9.

Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné J-M. Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. Biomarkers in cancer. 2018 janv. 18;10:1179299X18781095. https://doi.org/10.1177/1179299X18781095

Hack K, Cornelis G, Renzi F, Dogné J-M, Jonathan D, Inventeurs. USES OF DIPEPTIDYL PEPTIDASE 7 (DPP7) POLYPEPTIDE. C12N 9/ 64 A I. 2018 janv. 3.

Lozano O, Colaux JL, Laloy J, Alpan L, Dogné JM, Lucas S. Fast, asymmetric and nonhomogeneous clearance of SiC nanoaerosol assessed by micro-particle-induced x-ray emission. Nanomedicine. 2018 janv. 1;13(2). https://doi.org/10.2217/nnm-2017-0245

Courtois A, Makrygiannis G, Cheramy-Bien JP, Purnelle A, Pirotte B, Dogné JM et al. Therapeutic applications of prostaglandins and thromboxane A 2 inhibitors in abdominal aortic aneurysms. CurrentDrug Targets. 2018 janv. 1;19(11):1247-1255. https://doi.org/10.2174/1389450119666171227224314

Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogne J-M. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? TH Open. 2018;02(1):e68-e88. https://doi.org/DOI: 10.1055/s-0038-1624566

Siriez R, Evrard J, Dogne J-M, Pochet L, Gheldof D, Chatelain B et al. Betrixaban : Impact on routine and specific coagulation assays - A practical laboratory guide. Dans BJH - Belgian Journal of Hematology - Clinic: Abstracts - 33rd General Annual Meeting of the Belgian Hematology Society . 2018. p. 22. PP47

Siriez R, Evrard J, Dogne J-M, Pochet L, Gheldof D, Chatelain B et al. Betrixaban: Impact on routine and specific coagulation assays - Practical laboratory guidance. Dans International Society for Laboratory Hematology: Abstracts. 2018

Evrard J, Siriez R, Bouvy C, Laloy J, Mullier F, Dogne J-M et al.. Clot waveform analysis: Determination of optimal wavelength to assess the fibrin coagulation process. 2018. Poster présenté à64 th Annual International Society on Thrombosis and Haemostasis SSC meeting, Dublin, Irlande.

Evrard J, Siriez R, Themans P, Laloy J, Mullier F, Dogne J-M et al.. Clot waveform analysis for measuring and quantifying fibrin clot formation. 2018. Poster présenté à 64 th Annual International Society on Thrombosis and Haemostasis SSC meeting, Dublin, Irlande.

Laloy J, Haguet H, Alpan L, Raichman D, Dogné J-M, Lellouche J-P. Impact of functional inorganic nanotubes f-INTs-WS2 on hemolysis, platelet function and coagulation. Nano convergence. 2018;5(1):31. https://doi.org/10.1186/s40580-018-0162-1

Wannez A, Devalet B, Bouvy C, Dogne J-M, Mullier F. Study of the potential roles of extracellular vesicles in thrombosis associated with paroxysmal nocturnal hemoglobinuria: a cellular model. 2018. Poster présenté à Séminaire des checheurs Télévie 2018, Bruxelles, Belgique.

2017

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogne J-M. Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture. 2017. Poster présenté à 59th American Society of Hematology Annual Meeting and Exposition, Atlanta, États-Unis.

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogne J-M. In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions. 2017. Poster présenté à 59th



American Society of Hematology Annual Meeting and Exposition, Atlanta, États-Unis.

Reatul K, Palazzo C, Laloy J, Delvigne A-S, Vanslambrouck S, Jérôme C et al. Development and evaluation of injectable nanosized drug delivery systems for apigenin. International Journal of Pharmaceutics. 2017 nov. 5;532(2):757-768. https://doi.org/10.1016/j.ijpharm.2017.04.064

Bouvy C, Wannez A, Laloy J, Chatelain C, Dogné JM. Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo. Leukemia Research. 2017nov. 1;62:70-76. https://doi.org/10.1016/j.leukres.2017.09.014

Vornicu O, Larock AS, Dincq AS, Douxfils J, Dogné JM, Mullier F et al. Idarucizumab for the treatmentof hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opinion on Biological Therapy. 2017 oct. 3;17(10):1275-1296. https://doi.org/10.1080/14712598.2017.1349749

Sennesael A-L, Exner T, Chatelain B, Lessire S, Larock A-S, Vancraeynest C et al. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thrombosis Research. 2017 sept. 1;157:29-37. https://doi.org/10.1016/j.thromres.2017.06.034

Laloy J, Haguet H, Alpan L, Mancier V, Mejia J, Levi S et al. Characterization of core/shell Cu/Ag nanopowders synthesized by electrochemistry and assessment of their impact on hemolysis, platelet aggregation, and coagulation on human blood for potential wound dressing use. Journal of Nanoparticle Research. 2017 août 1;19(8). 266. https://doi.org/10.1007/s11051-017-3937-0

Wannez A, Devalet B, Bouvy C, Laloy J, Bihin B, Chatelain B et al. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thrombosis Research. 2017 août 1;156:142-148. https://doi.org/10.1016/j.thromres.2017.06.013

Sabor L, Raphaël M, Dogné J-M, Mullier F, Douxfils J. Heparin-calibrated chromogenic anti-Xa assaysare not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thrombosis Research. 2017 août 1;156:36-38. https://doi.org/10.1016/j.thromres.2017.05.024

Maignen F, Hauben M, Dogné JM. A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality. Therapeutic Advances in Drug Safety. 2017 juil. 1;8(7):231-244. https://doi.org/10.1177/2042098617704143

Dubois V, Dincq A-S, Douxfils J, Ickx B, Samama C-M, Dogné J-M et al. Perioperative management of patients on direct oral anticoagulants. Thrombosis journal. 2017 mai 15;15(1):14. 14. https://doi.org/10.1186/s12959-017-0137-1

Bouvy C, Wannez A, Chatelain C, Dogne J-M. Circulating microRNAs as biomarkers in diffuse large B-cell lymphoma: a pilot prospective longitudinal clinical study. Dans 22nd Congress Of The EuropeanHematology Association Madrid, Spain, June 22–25, 2017. 2017

Minet V, Dogné JM, Mullier F. Functional assays in the diagnosis of heparin-induced thrombocytopenia: A review. Molecules. 2017 avr. 1;22(4). 617. https://doi.org/10.3390/molecules22040617

Haguet H, Fichera O, Mejia Mendoza JH, Alpan L, Lucas S, Dogne J-M et al.. NANOGECO - Paint nanoparticles generated by atomization spray. Risk evaluation. 2017. Poster présenté à SRA Nano Risk Governance, Venise, Italie.

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogne J-M. Vascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia. Belgian Journal of Hematology Volume. 2017 mars;8(2):45-52.

Gheldof D, Haguet H, Dogne J-M, Bouvy C, Graux C, George F et al. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. Journal of Thrombosis and Thrombolysis. 2017 févr. 1;43(2):224-232. https://doi.org/10.1007/s11239-016-1471-z

Frère A, Baroni A, Hendrick E, Delvigne AS, Orange F, Peulen O et al. PEGylated and functionalized aliphatic polycarbonate polyplex nanoparticles for intravenous administration of HDAC5 siRNA in cancer therapy. ACS Applied Materials and Interfaces. 2017 janv. 25;9(3):2181-2195. https://doi.org/10.1021/acsami.6b15064

Salmonson T, Dogne JM, Janssen H, Burgos JG, Blake P. Non-vitamin-Koral anticoagulants and laboratory testing: Now and in the future: Views from a workshop at the European Medicines Agency (EMA). European Heart Journal - Cardiovascular Pharmacotherapy. 2017 janv. 1;3(1):42-47. https://doi.org/10.1093/ehjcvp/pvw032

Fichera O, Mejia Mendoza JH, Alpan L, Uhrner U, Laloy J, Lucas S et al.. Characterization and Novel Measurement Techniques of Aerosol-based Nanomaterials. 2017. Poster présenté à European



Aerosol Conference, Zurich, Suisse.

Bouvy C, Wannez A, Chatelain C, Dogne J-M. Circulating microRNAs as biomarkers in diffuse large B-cell lymphoma: a pilot prospective longitudinal clinical study. 2017. Poster présenté à 22nd Congress of European Hematology Association, Madrid, .

Fichera O, Mejia Mendoza JH, Laloy J, Alpan L, Lucas S, Dogne J-M. Detection and evaluation of nanoparticles-containing spray coating generated by atomization process. 2017. Poster présenté à 3rd Global Nanotechnology Congress and Expo, Dallas, États-Unis.

Douxfils J, Gheldof D, Derochette S, Tassignon J, Meinguet C, Guyaux M et al. Efficacy of a Novel Contact Pathway Inhibitor, Ir-CPI, on in vitro Clotting Induced by PCI Catheter Segment. Dans Research and practice in thrombosis and haemostasis: Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017. Vol 1. 2017. p. 1044-1045

Douxfils J, Gheldof D, Derochette S, Tassignon J, Meinguet C, Guyaux M et al.. Efficacy of a Novel Contact Pathway Inhibitor, Ir-CPI, on in vitro Clotting Induced by PCI Catheter Segment. 2017. Poster présenté à XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Allemagne.

Sabor L, Raphaël M, Dogne J-M, Mullier F, Douxfils J. Heparin Calibrated Anti-Xa Assays for the Measurement of Low Levels of Direct Factor Xa Inhibitors. Dans Research and practice in thrombosis and haemostasis: Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017. Vol 1. 2017. p. 1044

Sabor L, Raphaël M, Dogne J-M, Mullier F, Douxfils J. Heparin Calibrated Anti-Xa Assays for the Measurement of Low Levels of Direct Factor Xa Inhibitors. 2017. Poster présenté à XXVI Congress ofthe International Society on Thrombosis and Haemostasis, Berlin, Allemagne.

Haguet H, Douxfils J, Chatelain CJ, Graux C, Mullier F, Dogné J-M. Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture. Dans Abstract and Meeting Program of the 59th ASH Annual Meeting. Suppl 1 Ed. Vol 130. 2017. p. 1591-1591. (Blood).

Haguet H, Douxfils J, Chatelain CJ, Graux C, Mullier F, Dogné J-M. In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions. Dans Abstract and Meeting Program of the 59th ASH Annual Meeting. Suppl 1 Ed. Vol 130. 2017. p. 1592-1592. (Blood).

Sennesael A-L, Larock A-S, Douxfils J, Dogne J-M, Spinewine A, Mullier F. Measurement of Direct Oral Anticoagulants Levels in Patients Admitted for Bleeding Events: A Prospective Study. Dans Research and practice in thrombosis and haemostasis: Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017. 2017. p. 989

Sennesael A-L, Larock A-S, Douxfils J, Dogne J-M, Spinewine A, Mullier F. Measurement of Direct Oral Anticoagulants Levels in Patients Admitted for Bleeding Events: A Prospective Study. 2017. Poster présenté à XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Allemagne.

Wannez A, Devalet B, Bouvy C, Bihin B, Dogne J-M, Mullier F. Study of extracellular vesicles role sin the pathophysiology of thrombosis in paroxysmal nocturnal hemoglobinuria patients during eculizumab treatment: a pilot prospective longitudinal clinical study. 2017. Poster présenté à 22nd Congress of European Hematology Association, Madrid, .

Wannez A, Devalet B, Bouvy C, Bihin B, Dogne JM, Mullier F. Study of extracellular vesicles roles in the pathophysiology of thrombosis in paroxysmal nocturnal hemoglobinuria patients during eculizumab treatment: A pilot prospective longitudinal clinical study. Acta haematologica. 2017;102:62.

Wannez A, Devalet B, Bouvy C, Bihin B, Douxfils J, Dogne J-M et al. The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular Vesicles in Paroxysmal Nocturnal Hemoglobinuria Patients. Dans Research and practice in thrombosis and haemostasis: Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017. Vol 1. 2017. p. 1083

Wannez A, Devalet B, Bouvy C, Bihin B, Douxfils J, Dogne J-M et al.. The Impact of the Eculizumab on the Thrombogenicity Induced by Extracellular Vesicles in Paroxysmal Nocturnal Hemoglobinuria Patients. 2017. Poster présenté à XXVI Congress of the International Society on Thrombosis and Haemostasis, Berlin, Allemagne.

2016

Hack K, Renzi F, Hess E, Lauber F, Douxfils J, Dogné JM et al. Inactivation of human coagulation factor X by a protease of the pathogen Capnocytophaga canimorsus. Journal of thrombosis and haemostasis : JTH. 2016 déc. 28. https://doi.org/10.1111/jth.13605

Wannez A, Devalet B, Bouvy C, Bihin B, Chatelain C, Dogne J-M et al.. Impact of Eculizumab Treatment on the Amount and The Procoagulant Activity of Extracellular Vesicles in Paroxysmal



Nocturnal Hemoglobinuria Patients. 2016.

Bouvy C, Wannez A, Chatelain C, Dogne J-M. Transfer of Multidrug Resistance Among Acute Myeloid Leukemia Cells Via Extracellular Vesicles and Their Micrornas Cargo. Dans 58th ASH AnnualMeeting: Annual Meeting Abstracts. Blood Ed. Vol 128. 2016

Nchimi A, Courtois A, El Hachemi M, Touat Z, Drion P, Withofs N et al. Multimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model. European Radiology. 2016 juil. 1;26(7):2378-2386. https://doi.org/10.1007/s00330-015-4010-y

Haguet H, Douxfils J, Mullier F, Graux C, Chatelain C, Dogne J-M. Meta-analysis of the risks of arterialand venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukaemia. 2016. Poster présenté à 21st congress of the European Hematology Association, Copenhague, Danemark.

Douxfils J, Haguet H, Dogné JM. Multiple causes of cardiotoxic effects in patients with chronic myeloidleukemia - Reply. JAMA oncology. 2016 juin 1;2(6):829. https://doi.org/10.1001/jamaoncol.2016.1011

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J et al.. Application of a clot based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. 2016. Poster présenté à 62nd Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Montpellier, France.

Lessire S, Douxfils J, Pochet L, Dincq A-S, Larock A-S, Gourdin M et al.. Estimation of rivaroxaban plasma concentrations in the perioperative setting with or without heparin bridging: an ex vivo study using dedicated chromogenic assays. 2016. Poster présenté à 62nd Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Montpellier, France.

Sennesael A-L, Lessire S, Chatelain B, Larock A-S, Dogné J-M, Spinewine A et al.. Impact of apixaban on the Dilute Russell’s viper venom time: an ex-vivo study. 2016. Poster présenté à 62nd Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Montpellier, France.

Douxfils J, Legrand H, Sennesael A-L, Lessire S, Dincq A-S, Larock A-S et al.. Matrix effect of commercially available direct oral anticoagulant standards: A look through the limits and the need for standardization of current calibrators.. 2016. Poster présenté à 62nd Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Montpellier, France.

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J et al. Application of a clot based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Dans Abstracts of the 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis May 25–28, 2016. 2016. p. 142. VAS26 https://doi.org/10.1111/jth.13325

Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M, Douxfils J. Cardiovascular effect of BCR-ABL TKIs: a meta-analysis and systematic review of arterial and venous occlusive events. Dans Abstracts of the 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis May 25–28, 2016. 2016. p. 77. HEM08 https://doi.org/10.1111/jth.13325

Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M, Douxfils J. Cardiovascular effect of BCR-ABL TKIs: a meta-analysis and systematic review of arterial and venous occlusive events. 2016. Poster présenté à 62nd Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Montpellier, France.

Lessire S, Douxfils J, Pochet L, Dincq A-S, Larock A-S, Gourdin M et al. Estimation of rivaroxaban plasma concentrations in the perioperative setting with or without heparin bridging: an ex vivo study using dedicated chromogenic assays. Dans Abstracts of the 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis May 25–28, 2016. 2016. p. 21. CA30 https://doi.org/10.1111/jth.13325

Sennesael A-L, Lessire S, Chatelain B, Larock A-S, Dogné J-M, Spinewine A et al. Impact of apixaban on the Dilute Russell’s viper venom time: an ex-vivo study. Dans Abstracts of the 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis May 25–28, 2016. 2016. p. 9. CA05 https://doi.org/10.1111/jth.13325

Douxfils J, Legrand H, Sennesael A-L, Lessire S, Dincq A-S, Larock A-S et al. Matrix effect of commercially available direct oral anticoagulant standards: a look through the limits and the need for standardization of current calibrators. Dans Abstracts of the 62nd Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis May 25–28, 2016. 2016. p. 30. CA-54 https://doi.org/10.1111/jth.13325

Tantra R, Bolea E, Bouwmeester H, Rey-Castro C, David CA, Dogné JM et al. Solubility Part 1: Overview. Dans Nanomaterial Characterization: An Introduction. Wiley. 2016. p. 81-116



https://doi.org/10.1002/9781118753460.ch5

Bouckaert C, Serra S, Rondelet G, Dolusic E, Wouters J, Dogne J-M et al. Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors. European Journal of Medicinal Chemistry. 2016 mars 3;181-194. 110. https://doi.org/10.1016/j.ejmech.2016.01.023

Romero M, Leon-Gomez E, Lobysheva I, Rath G, Dogne J-M, Feron O et al. Effects of BM-573 on Endothelial dependent relaxation and increased blood pressure at early stages of atherosclerosis. PLoS ONE. 2016 mars 1;11(3). e0152579. https://doi.org/10.1371/journal.pone.0152579

Tantra R, Bouwmeester H, Bolea E, Rey-Castro C, David CA, Dogné JM et al. Suitability of analytical methods to measure solubility for the purpose of nanoregulation. Nanotoxicology. 2016 févr. 7;10(2):173-184. https://doi.org/10.3109/17435390.2015.1038661

Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. JAMA oncology. 2016 févr. 4. https://doi.org/10.1001/jamaoncol.2015.5932

Mullier F, Lessire S, De Schoutheete JC, Chatelain B, Deneys V, Mathieux V et al. Facing coagulation disorders after acute trauma. B-ENT. 2016 janv. 1;12(1):67-85.

Lessire S, Douxfils J, Pochet L, Dincq A-S, Larock A-S, Gourdin M et al. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2016. https://doi.org/10.1177/1076029616675968

Dincq A-S, Lessire S, Chatelain B, Gourdin M, Dogné J-M, Mullier F et al. Impact of the Direct Oral Anticoagulants on Activated Clotting Time. Journal of cardiothoracic and vascular anesthesia. 2016. https://doi.org/10.1053/j.jvca.2016.09.002

Douxfils J, Pochet L, Lessire S, Vancraeynest C, Dogné JM, Mullier F. Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless? TrAC - Trends in Analytical Chemistry. 2016. https://doi.org/10.1016/j.trac.2016.01.029

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogne J-M. Meta-analysis of the risks of arterialand venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukaemia. Haematologica : The hematology journal. 2016;101(s1):452-453.

Vornicu O, Larock AS, Douxfils J, Mullier F, Dubois V, Dogne JM et al. Minimisation of bleeding risks due to direct oral anticoagulants. European Medical Journal Hematology. 2016;4(1):78-90.

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opinion On Drug Safety. 2016;1-8. https://doi.org/10.1080/14740338.2017.1261824

Wannez A, Devalet B, Bouvy C, Mullier F, Chatelain B, Chatelain C et al.. Role of extracellular vesiclesin thrombosis in paroxysmal nocturnal hemoglobinuria patients. 2016. Poster présenté à The Fifth International Meeting of ISEV, Rotterdam, .

Wannez A, Bouvy C, Devalet B, Mullier F, Chatelain B, Chatelain C et al.. Role of Extracellular Vesicles in Thrombosis in Paroxysmal Nocturnal Hemoglobinuria patients. 2016. Poster présenté à General Annual Meeting 2016 of the Belgian Hematology Society, La Hulpe, Belgique.

Bouvy C, Wannez A, Mullier F, Chatelain C, Dogne J-M. Transfer of multidrug resistance between leukemia cells via extracellular vesicles. 2016. Poster présenté à The Fifth International Meeting of ISEV, Rotterdam, .

2015

Douxfils J, Haguet H, Chatelain C, Graux C, Dogne J-M. BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival. Dans Blood - 2015 ASH Annual Meeting Abstracts. Vol 126. 2015. p. 2785 - 2785

Douxfils J, Haguet H, Chatelain C, Graux C, Dogne J-M. BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival. 2015. Poster présenté à 57th ASH Annual Meeting and Exposition, Orlando, États-Unis.

Wannez A, Devalet B, Mullier F, Chatelain B, Chatelain C, Dogne J-M. The role of extracellular vesicles in Paroxysmal Nocturnal Hemoglobinuria. 2015. Poster présenté à Séminaire des chercheursTélévie, Gembloux, Belgique.

Sennesael A-L, Donne JM, Spinewine A. Optimizing the safe use of direct oral anticoagulants in older patients: A teachable moment. JAMA Internal Medicine. 2015 oct. 1;175(10):1608-1609.



https://doi.org/10.1001/jamainternmed.2015.3589

Bouckaert C, Serra S, Dolusic E, Rondelet G, Dogne J-M, Frederick R et al.. New benzopyrans as FXIIa inhibitors. 2015.

Lessire S, Douxfils J, Baudar J, Bailly N, Dincq AS, Gourdin M et al. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thrombosis Research. 2015 sept. 1;136(3):693-696. https://doi.org/10.1016/j.thromres.2015.07.018

Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: A review. European Journal of Haematology. 2015 sept. 1;95(3):190-198. https://doi.org/10.1111/ejh.12543

Laloy J, Lozano Garcia O, Alpan L, Masereel B, Toussaint O, Dogné JM et al. Limited inflammatory response in rats after acute exposure to a silicon carbide nanoaerosol. Journal of Nanoparticle Research. 2015 août 25;17(8). 346. https://doi.org/10.1007/s11051-015-3138-7

Douxfils J, Mullier F, Dogné JM. Dose tailoring of dabigatran etexilate: Obvious or excessive? Expert Opinion On Drug Safety. 2015 août 1;14(8):1283-1289. https://doi.org/10.1517/14740338.2015.1049995

de Fays L, Van Malderen K, De Smet K, Sawchik J, Verlinden V, Hamdani J et al. Use of paracetamol during pregnancy and child neurological development. Developmental Medicine and Child Neurology. 2015 août 1;57(8):718-724. https://doi.org/10.1111/dmcn.12745

Minet V, Alpan L, Mullier F, Toussaint O, Lucas S, Dogné JM et al. The euglobulin clot lysis time to assess the impact of nanoparticles on fibrinolysis. Journal of Nanoparticle Research. 2015 juil. 27;17(7). 317. https://doi.org/10.1007/s11051-015-3110-6

Minet V, Bailly N, Dogné JM, Mullier F. Platelet microparticle generation assay for heparin-induced thrombocytopenia diagnosis: How should we express the results? Thrombosis Research. 2015 juil. 1;136(1):175-177. https://doi.org/10.1016/j.thromres.2015.04.035

Bouckaert C, Serra S, Dogne J-M, Frederick R, Pochet L. The 2,5-dichlorophenyl fragment as startingpoint in the design of new FXIIa inhibitors. 2015. Poster présenté à ISTH 2015, .

Sennesael A-L, Douxfils J, Exner T, Chatelain B, Larock A-S, Dogne J-M et al.. A DRVVT-based assay to estimate the intensity of anticoagulation in patients treated with NOACS. 2015. Poster présenté à XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada.

Hack K, Douxfils J, Dogne J-M, Cornelis G. C. Canimorsus affects coagulation by proteolytic cleavageof factor X. 2015. Poster présenté à XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada.

Douxfils J, Del Bianco T, Baudar J, Lessire S, Chatelain B, Dogne J-M et al.. Impact of edoxaban on haemostasis diagnosis assays: Practical recommendations. 2015. Poster présenté à XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada.

Watelet JB, Dogne JM, Mullier F. Remodeling and Repair in Rhinosinusitis. Current Allergy and Asthma Reports. 2015 juin 23;15(6). 34. https://doi.org/10.1007/s11882-015-0531-3

Douxfils J, Del Bianco T, Baudar J, Lessire S, Chatelain B, Dogne J-M et al.. Impact of edoxaban on a large panel of routine and more specific coagulation assays. 2015. Poster présenté à XXV Congress of the International Society on Thrombosis and Haemostasis, Toronto, Canada.

Bouckaert C, Serra S, Dogne J-M, Frederick R, Pochet L. Design of new small molecular weight inhibitors of FXIIa. 2015. Poster présenté à 29émes Journées Franco-Belges de Pharmacochimie, Spa, Belgique.

Douxfils J, Chatelain B, Dogné J-M, Mullier F. Real-world variability in dabigatran levels in patients withatrial fibrillation: comment. Journal of thrombosis and haemostasis : JTH. 2015 juin 1;13(6):1166-1168.https://doi.org/10.1111/jth.12880

Mullier F, Douxfils J, Tamigniau A, Dogné JM, Horellou MH, Flaujac C et al. Anticoagulants directs oraux: Actualités pour les biologistes. Annales de biologie clinique. 2015 mai 1;73(3):333-344. https://doi.org/10.1684/abc.2015.1025

Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael A-L, Wallemacq P et al. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thrombosis Research. 2015 mai 1;135(5):852-860. https://doi.org/10.1016/j.thromres.2015.02.020

Watelet JB, Chatelain B, Eloy P, Dogne JM, Mullier F. Recruitment and activation of circulating neutrophils after sinus surgery. B-ENT. 2015 janv. 1;11(1):1-10.

Laloy J, Lozano O, Alpan L, Toussaint O, Rolin S, Masereel B et al.. Acute pulmonary toxicity of siliconcarbide nanoparticles in rats. Exposure in a whole-body model.. 2015. Poster présenté à NANOTOX



2014, 7th International Nanotoxicology Congress, Antalya, Turquie.

Sennesael A-L, Douxfils J, Exner T, Larock A-S, Dogné J-M, Spinewine A et al. A DRVVT-based assay to estimate the intensity of anticoagulation in patients treated with NOACS. Dans J Thromb Haemost. 2015 Jun;13 Suppl 2:1-997. doi: 10.1111/jth.12993.: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015.. 2015. p. 798. PO125-WED

Hack K, Douxfils J, Dogné J-M, Cornelis G. C. canimorsus affects coagulation by proteolytic cleavage of factor X. Dans J Thromb Haemost. 2015 Jun;13 Suppl 2:1-997. doi: 10.1111/jth.12993.: Abstracts ofthe XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015.. 2015. p. 616. PO299-TUE

Larock AS, Mullier F, Douxfils J, Dogné JM, Spinewine A. Criteria for prescribing dabigatrin extexilate and rivaroxaban really appropriate? Authors' reply. The Annals of pharmacotherapy. 2015;49(1):155. https://doi.org/10.1177/1060028014556118

Douxfils J, Chatelain B, Chatelain C, Dogné J-M, Mullier F. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thrombosis and Haemostasis. 2015;115(2). https://doi.org/10.1160/TH15-05-0415

Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Rönquist-Nii Y, Pohanka A et al. Estimation of dabigatranplasma concentrations in the preoperative setting: An ex vivo study using dedicated coagulation assays. Thrombosis and Haemostasis. 2015;113(4):862-869. https://doi.org/10.1160/TH14-09-0808

Douxfils J, Del Bianco T, Baudar J, Lessire S, Chatelain B, Dogné J-M et al. Impact of edoxaban on a large panel of routine of more specific coagulation assays. Dans J Thromb Haemost. 2015 Jun;13 Suppl 2:1-997. doi: 10.1111/jth.12993.: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015.. 2015. p. 297. PO092-MON

Douxfils J, Del Bianco T, Baudar J, Lessire S, Chatelain B, Dogné J-M et al. Impact of edoxaban on haemostasis diagnosis assays: practical recommendations. Dans J Thromb Haemost. 2015 Jun;13 Suppl 2:1-997. doi: 10.1111/jth.12993.: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015.. 2015. p. 531. PO063-TUE

Minet V, Alpan L, Mullier F, Lucas S, Dogne J-M, Laloy J. Impact of several nanoparticles on fibrinolysis. 2015. Poster présenté à NANOTOX 2014, 7th International Nanotoxicology Congress, Antalya, Turquie.

Douxfils J, Mani H, Minet V, Devalet B, Chatelain B, Dogné JM et al. Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations. BioMed research international. 2015;2015. 345138. https://doi.org/10.1155/2015/345138

Laloy J, Lozano O, Alpan L, Toussaint O, Rolin S, Masereel B et al.. Pulmonary toxicity after inhalationof silicon carbide nanoparticles in rat. 2015. Poster présenté à 4th NanoImpactNet Integrating Conference and 1st QNano Integrating Conference "From theory to practice - development, training and enabling nanosafety and health research", UCD, Dublin, Irlande.

Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Risk of cardiovascular events associated with BCR-ABL TKIs: a systematic review and meta-analysis. Dans J Thromb Haemost. 2015 Jun;13 Suppl 2:1-997. doi: 10.1111/jth.12993.: Special Issue: Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20–25, 2015. 2015. p. 141-142. OR126 https://doi.org/10.1111/jth.12993

Lozano Garcia O, Lison D, Escamilla-Rivera V, Mejia Mendoza JH, Toussaint O, Dogne J-M et al. Theimpact of instilled carbide nanoparticles on rat lungs: an in vivo perspective on acute intratracheal instillation. Journal of Physics : Conference Series. 2015;617(1). 012017. https://doi.org/DOI:10.1088/1742-6596/617/1/012017

Lozano Garcia O, Colaux J, Laloy J, Dogne J-M, Lucas S. What is the impact of Silicon Carbide nanoparticles to the mineral composition of rat lungs? A PIXE-μPIXE comparative study. Journal of Physics : Conference Series. 2015;617. 012016. https://doi.org/10.1088/1742-6596/617/1/012016

2014

Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: The appropriate use of hemostasis assays. Thrombosis journal. 2014 nov. 4;12(24):1-18. https://doi.org/10.1186/1477-9560-12-24

Laloy J, Minet V, Alpan L, Mullier F, Beken S, Toussaint O et al. Impact of silver nanoparticles on haemolysis, platelet function and coagulation. Nanomaterials and Nanotechnology. 2014 sept. 18;4. https://doi.org/10.5772/59346

Bouvy C, Gheldof D, Chatelain C, Mullier F, Dogne J-M. Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. Journal of Extracellular Vesicles. 2014 juil. 11. https://doi.org/10.3402/jev.v3.24400



Mullier F, Minet V, Bailly N, Devalet B, Douxfils J, Chatelain C et al. Platelet microparticle generation assay: A valuable test for immune heparin-induced thrombocytopenia diagnosis. Thrombosis Research. 2014 juin 30;133(6):1068-1073. https://doi.org/10.1016/j.thromres.2013.12.009

Minet V, Baudar J, Bailly N, Douxfils J, Laloy J, Lessire S et al. Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis Research. 2014 juin 30;133(6):1074-1078. https://doi.org/10.1016/j.thromres.2014.01.014

Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster J-Y et al. Dabigatran Etexilate and Riskof Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2014 juin 27;3(3). 000515. https://doi.org/10.1161/JAHA.113.000515

Mullier F, Vanpee D, Jamart J, Dubuc E, Bailly N, Douxfils J et al. Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2014 juin 1;25(4):309-315. https://doi.org/10.1097/MBC.0000000000000020

Laloy J, Lozano Garcia O, Alpan L, Mejia Mendoza JH, Toussaint O, Masereel B et al. Can TiC nanoparticles produce toxicity in oral administration to rats? Toxicology Reports. 2014 mai 12;1:172-187. https://doi.org/10.1016/j.toxrep.2014.03.004

Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: A review. Journal of Extracellular Vesicles. 2014 mars 24;3(1). 23304. https://doi.org/10.3402/jev.v3.23304

Laloy J, Mullier F, Alpan L, Mejia Mendoza JH, Lucas S, Chatelain B et al. A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: A practical guide. Nanotoxicology. 2014 mars 1;8(2):220-232. https://doi.org/10.3109/17435390.2013.788750

Tamigniau A, Douxfils J, Nicolas JB, Devalet B, Larock AS, Spinewine A et al. Pourquoi, quand et comment doser les nouveaux anticoagulants oraux? Revue médicale suisse. 2014 févr. 5;10(416):326-333.

Maignen F, Hauben M, Hung E, Holle LV, Dogne JM. A conceptual approach to the masking effect of measures of disproportionality. Pharmacoepidemiology and Drug Safety. 2014 févr. 1;23(2):208-217. https://doi.org/10.1002/pds.3530

Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiology and Drug Safety. 2014 févr. 1;23(2):195-207. https://doi.org/10.1002/pds.3529

Lozano Garcia O, Mejia Mendoza JH, Laloy J, Alpan L, Toussaint O, Dogne J-M et al. Evaluation of metal trace detachment from dosing pumps using PIXE. Nuclear Instruments and Methods in PhysicsResearch, Section B: Beam Interactions with Materials and Atoms. 2014 janv. 31. https://doi.org/10.1016/j.nimb.2014.01.006

Arlett P, Portier G, De Lisa R, Blake K, Wathion N, Dogne JM et al. Proactively managing the risk of marketed drugs: Experience with the EMA Pharmacovigilance Risk Assessment Committee. Nature Reviews Drug Discovery. 2014 janv. 1;13(5):395-397. https://doi.org/10.1038/nrd3713-c1

Larock A-S, Mullier F, Sennesael A-L, Douxfils J, Devalet B, Chatelain C et al. Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation: A Prospective Study. The Annals of pharmacotherapy. 2014;48(10):1258-1268. https://doi.org/10.1177/1060028014540868

Laloy J, Minet V, Alpan L, Mullier F, Beken S, Toussaint O et al.. Assessment of silver nanoparticles onhemolysis, platelet adhesion and coagulation. Proposal of recommended safety margin for these tree parameters. 2014. Poster présenté à NANOTOX 2014, 7th International Nanotoxicology Congress, Antalya, Turquie.

Lessire S, Dincq A-S, Douxfils J, Devalet B, Nicolas J-B, Spinewine A et al. Erratum to "Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants". BioMed research international. 2014;2014. 347031. https://doi.org/10.1155/2014/347031

Douxfils J, Lessire S, Dincq A-S, Gourdin M, Gheldof D, Baudar J et al.. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex-vivo study using dedicated coagulation assays.. 2014. Poster présenté à 56th ASH Annual Meeting and Exposition , San Francisco, États-Unis.

Douxfils J, Lessire S, Dincq A-S, Gourdin M, Baudar J, Chatelain B et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex-vivo study using dedicated coagulation assays. Dans Blood - 2014 ASH Annual Meeting Abstracts. Vol 124. 2014

Laloy J, Mullier F, Robert S, Alpan L, Marbehant C, Mejia Mendoza JH et al.. Impact of carbon



nanomaterials on platelet function: evaluation of the suitability of different methods and study of their biological effect. 2014. Poster présenté à 23rd ISTH (International Society of Thrombosis and Hemostasis) Meeting, Kyoto, Japon.

Douxfils J, Remacle S, Lessire S, Dincq A-S, Gourdin M, Chatelain B et al. Interest of thrombin time inthe periprocedural management for patients on dabigatran etexilate. Dans Journal of Thrombosis and Haemostasis. 2014 Jun;12 Suppl 1:1-117. 2014

Douxfils J, Remacle S, Lessire S, Dincq A-S, Gourdin M, Chatelain B et al.. Interest of thrombin time in the periprocedural management for patients on dabigatran etexilate. 2014. Poster présenté à 60th Annual SSC Meeting of the International Society on Thrombosis and Haemostasis, Milwaukee, États-Unis.

Remacle S, Lessire S, Douxfils J, Dincq A-S, Gourdin M, Chatelain B et al. INTEREST OF THROMBIN TIME IN THE PERI-PROCEDURAL MANAGEMENT FOR PATIENTS ON DABIGATRAN ETEXILATE. Dans INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. Vol 36. 2014. p. 95-95

Remacle S, Lessire S, Douxfils J, Dincq A-S, Gourdin M, Chatelain B et al.. INTEREST OF THROMBIN TIME IN THE PERI-PROCEDURAL MANAGEMENT FOR PATIENTS ON DABIGATRAN ETEXILATE. 2014. Poster présenté à XXVIIth International Symposium on Technological Innovations in Laboratory Hematology, The Hague, Pays-Bas.

Larock AS, Mullier F, Laloux P, Douxfils J, Dogné JM, Spinewine A. Les mirages des nouveaux anticoagulants oraux. Journal de Pharmacie de Belgique. 2014;(1):38-41.

Dincq A-S, Lessire S, Douxfils J, Dogné J-M, Gourdin M, Mullier F. Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. BioMed research international. 2014;2014. 385014. https://doi.org/10.1155/2014/385014

Gheldof D, Chatelain C, Dogné J-M, Mullier F. Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thrombosis Research. 2014. https://doi.org/10.1016/j.thromres.2014.05.001

Gheldof D, Mullier F, Bailly N, Devalet B, Dogné J-M, Chatelain B et al. Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. Thrombosis Research. 2014;133(3):433-9. https://doi.org/10.1016/j.thromres.2013.11.008

Garin P, Mullier F, Gheldof D, Dogne J-M, Putz L, Van Damme JP. Platelet-rich fibrin (PRF): an autologous packing material for middle ear microsurgery. Physical Review B - Condensed Matter and Materials Physics. 2014;10(1):27-34.

Lessire S, Dincq AS, Douxfils J, Devalet B, Nicolas JB, Spinewine A et al. Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. BioMed research international. 2014;2014. 616405. https://doi.org/10.1155/2014/616405

Mullier F, Douxfils J, Tamigniau A, Dogne J-M, Horellou M-H, Flaujac C et al. Suivi biologique des patients sous nouveaux anticoagulants oraux: qui, quand, comment ? Feuillets de Biologie. 2014;55(319):5-14.

Laloy J, Lozano O, Alpan L, Mejia Mendoza JH, Toussaint O, Masereel B et al.. Toxicological evaluation of TiC nanoparticles orally administered in a rat model. 2014. Poster présenté à Nanosafe 2012: Third international conference on safe production and use of nanomaterials, Grenoble, France.

Douxfils J, Baudar J, Devalet B, Samama MM, Chatelain B, Dogne J-M et al. What is the best time sampling for the two direct oral anticoagulants (DOACs), dabigatran and rivaroxaban? Dans Journal of Thrombosis and Haemostasis. 2014 Jun;12 Suppl 1:1-117. 2014

Douxfils J, Baudar J, Devalet B, Samama MM, Chatelain B, Dogne J-M et al.. What is the best time sampling for the two direct oral anticoagulants (DOACs), dabigatran and rivaroxaban?. 2014. Poster présenté à 60th Annual SSC Meeting of the International Society on Thrombosis and Haemostasis, Milwaukee, États-Unis.

2013

Draoui N, Schicke O, Fernandes A, Drozak X, Nahra F, Dumont A et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorganic and Medicinal Chemistry. 2013 nov. 15;21(22):7107-7117. https://doi.org/10.1016/j.bmc.2013.09.010

Bambi-Nyanguile SM, Hanson J, Ooms A, Alpan L, Kolh P, Dogne J-M et al. Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5- cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists. European Journal of Medicinal Chemistry. 2013 sept. 23;65:32-40. https://doi.org/10.1016/j.ejmech.2013.04.033

Minet V, Bailly N, Douxfils J, Osselaer JC, Laloy J, Chatelain C et al. Assessment of the performances



of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: A retrospective study. Thrombosis Research. 2013 sept. 1;132(3):352-359. https://doi.org/10.1016/j.thromres.2013.06.004

Douxfils J, Dogné J-M, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RE et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and Haemostasis. 2013 sept.;110(3):543-549. https://doi.org/10.1160/TH13-03-0202

Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné J-M et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thrombosis and Haemostasis. 2013 juil. 11;110(4):723-731. https://doi.org/10.1160/TH13-04-0274

Gheldof D, Mullier F, Chatelain B, Dogne J-M, Chatelain C. Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2013 juil.;24(5):567-572. https://doi.org/10.1097/MBC.0b013e328360a56e

Douxfils J, Dogné J-M, Mullier F, Chatelain B, Chatelain C. Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide. Thrombosis and Haemostasis. 2013 juin 13;110(2):283-294. https://doi.org/10.1160/TH12-12-0898

Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F et al. Standardization of pre-analytical variables in plasma microparticle determination: Results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. Journal of Thrombosis and Haemostasis.2013 juin 1;11(6):1190-1193. https://doi.org/10.1111/jth.12207

Neels P, Van Damme P, Van Ranst M, Dogne J-M. Human papillomavirus vaccines: Understanding the benefit-risk. Annals of Medicine. 2013 mai 1;45(3):203-205. https://doi.org/10.3109/07853890.2012.700117

Mullier F, Bailly N, Chatelain C, Chatelain B, Dogné J-M. Pre-analytical issues in the measurement of circulating microparticles: Current recommendations and pending questions. Journal of thrombosis and haemostasis : JTH. 2013 avr. 1;11(4):693-696. https://doi.org/10.1111/jth.12171

Gheldof D, Hardij J, Cecchet F, Chatelain B, Dogne J-M, Mullier F. Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. Journal of Extracellular Vesicles. 2013 mars 18;2:19728-19738. https://doi.org/10.3402/jev.v2i0.19728

Douxfils J, Michel S, Beauloye C, Goethals M, Hainaut P, Heidbuchel H et al. Rivaroxaban (Xarelto®):Guide de la pratique officinale. Journal de Pharmacie de Belgique. 2013 mars 1;(1):28-36.

Minet V, Douxfils J, Bailly N, Osselaer J-C, Chatelain C, Elalamy I et al. Acustar HIT-IGG and heparin-induced multiple electrode aggregometry: a useful combination for rapid diagnosis of type-II HIT. DansJournal of Thrombosis and Haemostasis. 2013 Dec;11 Suppl 3:1-105. 2013

Minet V, Douxfils J, Bailly N, Osselaer J-C, Chatelain C, Elalamy I et al.. Acustar HIT-IGG and heparin-induced multiple electrode aggregometry: a useful combination for rapid diagnosis of type-II HIT. 2013.Poster présenté à 58th Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Liverpool, Royaume-Uni.

Douxfils J, Mullier F, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al. Apixaban: Safety, usefulness and practical details of laboratory monitoring. Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322. 2013

Douxfils J, Mullier F, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al.. Apixaban: Safety, usefulness and practical details of laboratory monitoring. 2013. Poster présenté à XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Pays-Bas.

Lopez-Santos C, Colaux J, Laloy J, Fransolet M, Mullier F, Michiels C et al. Bioactivity and hemocompatibility study of amorphous hydrogenated carbon coatings produced by pulsed magnetrondischarge. Journal of Biomedical Materials Research - Part A. 2013;101 A(6):1800-1812. https://doi.org/10.1002/jbm.a.34489

Hardij J, Cecchet F, Berquand A, Gheldof D, Chatelain C, Mullier F et al. Characterisation of tissue factor-bearing extracellular vesicles with AFM: comparison of air-tapping-mode AFM and liquid Peak Force AFM. Journal of Extracellular Vesicles. 2013;2.

Douxfils J, Tamigniau A, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al. Comparison of Biophen DiXaI®, Prothrombin Time With a Reference HPLC-MS/MS Method to Monitor Patients Receiving Rivaroxaban. Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322. 2013

Douxfils J, Tamigniau A, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al.. Comparison of Biophen DiXaI®, Prothrombin Time With a Reference HPLC-MS/MS Method to Monitor Patients



Receiving Rivaroxaban. 2013. Poster présenté à XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Pays-Bas.

Douxfils J, Classen J-F, Baudar J, Walbrecq S, Chatelain C, Chatelain B et al. Comparison of Calibrated Automated Thrombogram and chronometric or chromogenic assays for the monitoring of DOACs in patients with non-valvular atrial fibrillation. Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322. 2013

Douxfils J, Classen J-F, Baudar J, Walbrecq S, Chatelain C, Chatelain B et al.. Comparison of Calibrated Automated Thrombogram and chronometric or chromogenic assays for the monitoring of DOACs in patients with non-valvular atrial fibrillation.. 2013. Poster présenté à XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Pays-Bas.

Douxfils J, Dogne J-M, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RIE et al. Comparison of Hemoclot Thrombin Inhibitor® and activated partial thromboplastin time with a reference UPLC-MS/MS method to monitor patients receiving Dabigatran Etexilate. Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322. 2013

Douxfils J, Dogne J-M, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RIE et al.. Comparison of Hemoclot Thrombin Inhibitor® and activated partial thromboplastin time with a reference UPLC-MS/MS method to monitor patients receiving Dabigatran Etexilate. 2013. Poster présenté à XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Pays-Bas.

Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster J-Y et al.. Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. 2013. Poster présenté à 55th ASH Annual Meeting and Exposition, New Orleans, États-Unis.

Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster J-Y et al. Dabigatran Etexilate and RiskOf Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. Dans Blood 2013 122:3633; published ahead of print December 6, 2013. 2013

Douxfils J, Vanhoutteghem A, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al. Dilute Russell Viper Venom Time: A useful assay for the monitoring of direct oral anticoagulants in patients? Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322. 2013

Douxfils J, Vanhoutteghem A, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al.. Dilute Russell Viper Venom Time: A useful assay for the monitoring of direct oral anticoagulants in patients?. 2013. Poster présenté à XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Pays-Bas.

Douxfils J, Tamigniau A, Chatelain B, Devalet B, Wallemacq P, Hjemdahl P et al.. Dilute Russell Viper Venom Time: A Useful Assay for the Monitoring of Direct Oral Anticoagulants in Patients?. 2013. Poster présenté à 21th Annual Meeting of the Belgian Society on Thrombosis and Haemostasis, La Hulpe, Belgique.

Douxfils J, Tamigniau A, Chatelain B, Devalet B, Wallemacq P, Hjemdahl P et al. Dilute Russell Viper Venom Time: A Useful Assay for the Monitoring of Direct Oral Anticoagulants in Patients? Dans Abstracts of the 21th Annual Meeting of the Belgian Society on Thrombosis and Haemostasis. 2013

Douxfils J, Pothen L, Mullier F, Dogne J-M, Hainaut P. Duration of Anticoagulation in Venous Thromboembolism : a Retrospective Analysis of a Large Cohort in a Belgian Disease Registry. 2013. Poster présenté à 21th Annual Meeting of the Belgian Society on Thrombosis and Haemostasis, La Hulpe, Belgique.

Douxfils J, Pothen L, Mullier F, Dogne J-M, Hainaut P. Duration of Anticoagulation in Venous Thromboembolism : a Retrospective Analysis of a Large Cohort in a Belgian Disease Registry. Dans Abstracts of the 21th Annual Meeting of the Belgian Society on Thrombosis and Haemostasis. 2013

Hainaut P, Douxfils J, Pothen L, Mullier F, Dogne J-M. Duration of anticoagulation in venous thromboembolism (VTE) : a retrospective analysis of a large Belgian cohort.. 2013. Poster présenté à 18th Annual Congress of the "Société Belge de Médecine Interne", Bruxelles, Belgique.

Hainaut P, Douxfils J, Pothen L, Mullier F, Dogne J-M. Duration of anticoagulation in venous thromboembolism (VTE) : a retrospective analysis of a large Belgian cohort. Dans Acta Clinica Belgica. Vol 68. 2013. p. 460-460

Douxfils J, Buckinx F, Minet V, Mullier F, Rabenda V, Reginster J-Y et al. Effect of dabigatran etexilate on the risk of myocardial infarction and other cardiac events: A systematic review and updated dose-response meta-analysis of randomized controlled trials. Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322 . 2013

Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné J-M, Bäck M. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth



muscle cells. Biochemical and Biophysical Research Communications. 2013;441(2):393-398. https://doi.org/10.1016/j.bbrc.2013.10.078

Lozano Garcia O, Mejia Mendoza JH, Piret J-P, Saout C, Dogne J-M, Toussaint O et al. How does thedeposited dose of oxide nanomaterials evolve in an in vitro assay? Journal of Physics : Conference Series. 2013;429(1). 012013. https://doi.org/10.1088/1742-6596/429/1/012013

Douxfils J, Mullier F, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al. Impact of apixaban on haemostasis diagnosis assays: Practical recommendations. Dans Journal of Thrombosis and Haemostasis. 2013 Jul;11 Suppl 2:1-1322. 2013

Douxfils J, Mullier F, Classen J-F, Baudar J, Walbrecq S, Chatelain C et al.. Impact of apixaban on haemostasis diagnosis assays: Practical recommendations. 2013. Poster présenté à XXIV Congress of the International Society of Thrombosis and Haemostasis, Amsterdam, Pays-Bas.

Douxfils J, Mullier F, Chatelain C, Chatelain B, Dogne J-M. Impact of CYP3A4*1G Polymorphism on plasmatic concentration profile of rivaroxaban (Xarelto) assessed by coagulation assays. Dans Journal of Thrombosis and Haemostasis. 2013 Dec;11 Suppl 3:1-105. 2013

Douxfils J, Mullier F, Chatelain C, Chatelain B, Dogne J-M. Impact of CYP3A4*1G Polymorphism on plasmatic concentration profile of rivaroxaban (Xarelto) assessed by coagulation assays. 2013. Posterprésenté à 58th Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Liverpool, Royaume-Uni.

Douxfils J, Tamigniau A, Chatelain B, Devalet B, Wallemacq P, Hjemdahl P et al.. Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?. 2013. Poster présenté à 55th ASH Annual Meeting and Exposition, New Orleans, États-Unis.

Douxfils J, Tamigniau A, Chatelain B, Devalet B, Wallemacq P, Hjemdahl P et al. Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate? Dans Blood 2013 122:3634; published ahead of print December 6, 2013. 2013

Mullier F, Douxfils J, Baes H, Baudar J, Lessire S, Gourdin M et al.. Is Thrombin Time Useful To GuidePeri-Procedural Management For Patients On Dabigatran Etexilate?: An In Vitro Validation Study. 2013. Poster présenté à 55th ASH Annual Meeting and Exposition, New Orleans, États-Unis.

Mullier F, Douxfils J, Baes H, Baudar J, Lessire S, Gourdin M et al. Is Thrombin Time Useful To Guide Peri-Procedural Management For Patients On Dabigatran Etexilate?: An In Vitro Validation Study. Dans Blood 2013 122:2388; published ahead of print December 6, 2013. 2013

Lopez-Santos C, Colaux J, Laloy J, Fransolet M, Mullier F, Michiels C et al.. Study of biocompatible and hemocompatible properties of amorphous hydrogenated carbon coatings produced by pulsed magnetron discharge.. 2013. Poster présenté à 1st Meeting NanoMED, Londres, Royaume-Uni.

Lozano Garcia O, Toussaint O, Dogne J-M, Lucas S. The use of PIXE for engineered nanomaterials quantification in complex matrices. Journal of Physics : Conference Series. 2013;429(1). 012010. https://doi.org/10.1088/1742-6596/429/1/012010

2012

Douxfils J, Mullier F, Dogné J-M, Loosen C, Chatelain B, Chatelain C. Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thrombosis Research. 2012 déc. 1;130(6):956-966. https://doi.org/10.1016/j.thromres.2012.09.004

Gourdin M, Dubois P, Mullier F, Chatelain B, Dogné J-M, Marchandise B et al. The effect of clonidine, an alpha-2 adrenergic receptor agonist, on inflammatory response and postischemic endothelium function during early reperfusion in healthy volunteers. Journal of cardiovascular pharmacology. 2012 déc.;60(6):553-60. https://doi.org/10.1097/FJC.0b013e31827303fa

Lozano Garcia O, Laloy J, Alpan L, Mejia Mendoza JH, Rolin S, Toussaint O et al. Effects of SiC nanoparticles orally administered in a rat model: Biodistribution, toxicity and elemental composition changes in feces and organs. Toxicology and applied pharmacology. 2012 oct. 15;264(2):232-45. https://doi.org/10.1016/j.taap.2012.08.004

Lozano Garcia O, Mejia Mendoza JH, Tabarrant T, Lucas S, Masereel B, Dogné J-M et al. Erratum: Quantification of nanoparticles in aqueous food matrices using Particle-Induced X-ray Emission (Analytical and Bioanalytical Chemistry DOI: 10.1007/s00216-012-5895-9). Analytical and Bioanalytical Chemistry. 2012 août 1;404(2):623. https://doi.org/10.1007/s00216-012-6148-7

Lozano Garcia O, Mejia Mendoza JH, Tabarrant T, Masereel B, Dogné J-M, Toussaint O et al. Quantification of nanoparticles in aqueous food matrices using Particle-Induced X-ray Emission. Analytical and Bioanalytical Chemistry. 2012 juil. 1;403(10):2835-41. https://doi.org/10.1007/s00216-012-5895-9



Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné J-M. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thrombosis and Haemostasis. 2012 mai;107(5):985-97. https://doi.org/10.1160/TH11-11-0804

Sternotte A, Douxfils J, Mullier F, Dogné J-M, Chatelain B, Chatelain C et al. Dabigatran bij voorkamerfibrillatie: Klinische studies, voordelen en beperkingen. Farmaceutisch Tijdschrift voor Belgie. 2012 mars 1;89(1):8-17.

Laloy J, Robert S, Marbehant C, Mullier F, Mejia Mendoza JH, Piret J-P et al. Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. Nanotoxicology. 2012 mars 1;6(2):213-232. https://doi.org/10.3109/17435390.2011.569096

Sternotte A, Douxfils J, Mullier F, Dogné J-M, Chatelain B, Chatelain C et al. Dabigatran dans la fibrillation auriculaire: Études cliniques, intérêts et limites. Journal de Pharmacie de Belgique. 2012 mars;67(1):8-17.

Mullier F, Daliphard S, Garand R, Hanet F, Dekeyser M, Cornet Y et al. L'association des neutrophiles hypogranulaires et vacuolisés à l'érythrophagocytose par les neutrophiles est un marqueur utile dans les syndromes myélodysplasiques avec del(20q) ou ider(20q): une étude multicentrique. Immuno-Analyse et Biologie Specialisee. 2012 févr. 1;27(1):7-19. https://doi.org/10.1016/j.immbio.2012.01.002

Mullier F, Daliphard S, Garand R, Dekeyser M, Cornet Y, Luquet I et al. Morphology, cytogenetics, andsurvival in myelodysplasia with del(20q) or ider(20q): a multicenter study. Annals of hematology. 2012 févr.;91(2):203-13. https://doi.org/10.1007/s00277-011-1286-0

Mullier F, Rahier J-F, Maignen F, Cornet Y, Graux C, Chatelain C et al. A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine. Acta haematologica. 2012;128(1):1-6. https://doi.org/10.1159/000337046

Mullier F, Laloy J, Robert S, Alpan L, Mejia Mendoza JH, Piret J-P et al. Assessment of different methods studying the impact of carbon nanomaterials on platelet function. Immuno-analyse Biologie Spécialisée. 2012;27(1):41. https://doi.org/10.1016/j.immbio.2011.11.023

Laloy J, Robert S, Marbehant C, Mullier F, Mejia Mendoza JH, Piret J-P et al.. Calibrated thrombin generation test (cTGT): a powerful original method to assess the procoagulant activity of nanomaterials. 2012. Poster présenté à 23rd ISTH (International Society of Thrombosis and Hemostasis) Meeting, Kyoto, Japon.

Mullier F, Vanpee D, Amart J, Dubuc E, Cornet Y, Chatelain C et al. Comparison of five D-dimer reagents and application of an age adjusted cut-off for the diagnosis of venous thromboembolic disease in emergency department. Immuno-analyse Biologie Spécialisée. 2012;27(1):42. https://doi.org/10.1016/j.immbio.2011.11.025

Gheldof DDG, Mullier F, Chatelain B, Dogne J-M, Chatelain C. Comparison of the Use of TFPI Inhibition and Plasma Dilution to Increase the Sensitivity of Thrombin Generation Assay to Measure the Procoagulant Activity of Microvesicles. Dans BLOOD. Vol 120. 2012

Douxfils J, Mullier F, Robert S, Chatelain B, Chatelain C, Dogné J-M. Dabigatran: Safety, usefulness and practical details of point measurement. Dans Abstracts of the 27th Annual Meeting of the Belgian Hematological Society. 2012

Douxfils J, Mullier F, Robert S, Chatelain B, Chatelain C, Dogné J-M. Dabigatran: Safety, usefulness and practical details of point measurement.. 2012. Poster présenté à 27th General Annual Meeting of the Belgian Hematological Society., Liège, Belgique.

Laloy J, Lozano O, Alpan L, Toussaint O, Rolin S, Dogne J-M et al.. Development and validation of a whole-body inhalation exposure model for the exposition of rats to nanoparticle aerosol. 2012. Poster présenté à 4th NanoImpactNet Integrating Conference and 1st QNano Integrating Conference "From theory to practice - development, training and enabling nanosafety and health research", UCD, Dublin,Irlande.

Douxfils J, Mullier F, Chatelain C, Chatelain B, Jean-Michel D, Dogne J-M. Impact of Apixaban On a Large Panel of Routine or More Specific Coagulation Assays. Dans Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 2275. . 2012

Douxfils J, Mullier F, Chatelain C, Chatelain B, Jean-Michel D, Dogne J-M. Impact of Apixaban On a Large Panel of Routine or More Specific Coagulation Assays.. 2012. Poster présenté à 54th ASH Annual Meeting and Exposition, Atlanta, GA, États-Unis.

Gheldof DDG, Mullier F, Chatelain B, Dogne J-M, Chatelain C. Implication of Tissue Factor Bearing Microvesicles in Hypercoagulable State in Acute Promyelocytic Leukemia. Dans BLOOD. Vol 120. 2012

Mullier F, Bailly N, Cornet Y, Robert S, Osselaer J-C, Chatelain C et al. Platelet microparticle



generation assay: A valuable predictor of clinical outcome in heparin-induced thrombocytopenia diagnosis. Immuno-analyse Biologie Spécialisée. 2012;27(1):41. https://doi.org/10.1016/j.immbio.2011.11.022

Mullier F, Bailly N, Chatelain C, Pr MD, Chatelain B, Dogné JM et al. Quantification and characterisation of microvesicles: Applications in hereditary spherocytosis, type-II heparin-induced thrombocytopenia and cancer. Belgian Journal of Hematology Volume. 2012;3(4):157.

Douxfils J, Mullier F, Robert S, Chatelain B, Chatelain C, Dogné J-M. Rivaroxaban: Safety, usefulness and practical details of point measurement. Dans Abstracts of the 27th Annual Meeting of the Belgian Hematological Society. 2012

Douxfils J, Mullier F, Robert S, Chatelain B, Chatelain C, Dogné J-M. Rivaroxaban: Safety, usefulness and practical details of point measurement.. 2012. Poster présenté à 27th General Annual Meeting of the Belgian Hematological Society., Liège, Belgique.

Mullier F, Poncelet P, Bailly N, Robert S, Lacroix R, Garnache-Ottou F et al. Separation index: A usefultool to follow up and compare instrument performance for microparticle analysis by flow cytometry. Immuno-analyse Biologie Spécialisée. 2012;27(1):43. https://doi.org/10.1016/j.immbio.2011.11.028

Douxfils J, Mullier F, Loosen C, Chatelain B, Dogné J-M, Chatelain C. Successful switching from acenocoumarol to rivaroxaban in a patient with CYP3A4*1G polymorphism. Dans Abstracts of the 27th Annual Meeting of the Belgian Hematological Society. 2012

Douxfils J, Mullier F, Loosen C, Chatelain B, Dogné J-M, Chatelain C. Successful switching from acenocoumarol to rivaroxaban in a patient with CYP3A4*1G polymorphism. 2012. Poster présenté à 27th General Annual Meeting of the Belgian Hematological Society., Liège, Belgique.

Mullier F, Douxfils J, Chatelain C, Chatelain B, Dogne J-M. Thrombin Generation Assay Is Superior to Traditional Coagulometric and Chromogenic Assays to Monitor New Oral Anticoagulants. 2012. Poster présenté à 54th ASH Annual Meeting and Exposition, Atlanta, GA, États-Unis.

Mullier F, Douxfils J, Chatelain C, Chatelain B, Dogne J-M. Thrombin Generation Assay Is Superior to Traditional Coagulometric and Chromogenic Assays to Monitor New Oral Anticoagulants. Dans Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 1169. 2012

Mullier F, Varin E, Gheldof D, Hardij J, Robert S, Bailly N et al. Thrombin generation, flow cytometry and electron microscopy is a useful combination to study tissue-factor bearing microparticles in thrombosis associated with breast cancer. Immuno-analyse Biologie Spécialisée. 2012;27(1):43. https://doi.org/10.1016/j.immbio.2011.11.027

Latger-Cannard V, Mullier F, Toussaint-Hacquard M, Hurtaud M-F, Bailly N, Dogné J-M et al. Validationand assessment of mepacrine testing in delta storage pool disease: A 3-centre study. Immuno-analyse Biologie Spécialisée. 2012;27(1):43-44. https://doi.org/10.1016/j.immbio.2011.11.029

Laloy J, Robert S, Marbehant C, Mullier F, Mejia Mendoza JH, Piret J-P et al. Validation of the calibrated thrombin generation test (cTGT) as the gold standard assay to assess the procoagulant activity of nanomaterials. Immuno-analyse Biologie Spécialisée. 2012;27(1):42. https://doi.org/10.1016/j.immbio.2011.11.024

2011

Mullier F, Bailly N, Chatelain C, Dogné JM, Chatelain B. More on calibration for the measurement of microparticles: needs, interests, and limitations of calibrated polystyrene beads for flow cytometry-based quantification of biological microparticles. Journal of thrombosis and haemostasis : JTH. 2011 août;9(8):1679-2. https://doi.org/10.1111/j.1538-7836.2011.04386.x

Mullier F, Lainey E, Fenneteau O, Da Costa L, Schillinger F, Bailly N et al. Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. Annals of hematology. 2011 juil.;90(7):759-68. https://doi.org/10.1007/s00277-010-1138-3

Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011 juin;99(3):424-31. https://doi.org/10.1016/j.radonc.2011.05.045

Minet V, Bailly N, Douxfils J, Osselaer JC, Chatelain C, Elalamy L et al. AcuStar HIT-IgG and heparin-induced multiple electrode aggregometry: a useful combination for rapid diagnosis of type-II HIT. DansAbstracts of the 19th Annual Meeting of the Belgian Society on Thrombosis and Haemostasis. 2011

Minet V, Bailly N, Douxfils J, Osselaer JC, Chatelain C, Elalamy L et al.. AcuStar HIT-IgG and heparin-induced multiple electrode aggregometry: a useful combination for rapid diagnosis of type-II HIT. 2011.Poster présenté à 19th Annual Meeting of the Belgian Society on Thrombosis and Hemostasis, Brussels, Belgique.

Cherdon C, Ooms A, Sakalihassan N, Defraigne J-O, Rolin S, Michiels C et al. BM-573 inhibits the



development of early atherosclerotic lesions in Apo e deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. 2011;94:124-132. https://doi.org/10.1016/j.prostaglandins.2011.03.001

Robert S, Rolin S, Douxfils J, Hardij J, Varin E, Chatelain B et al. Characterization of naftidrofuryl as a thromboxane receptor antagonist. Dans Journal of Thrombosis and Haemostasis. 2011 Jul;9 Suppl 2:1-1055. 2011

Robert S, Rolin S, Douxfils J, Hardij J, Varin E, Chatelain B et al.. Characterization of naftidrofuryl as a thromboxane receptor antagonist. 2011. Poster présenté à XXIII Congress of the International Societyof Thrombosis and Haemostasis and 57th Annual SSC Metting, Kyoto, Japon.

Mullier F, Douxfils J, Robert S, Devel P, Chatelain C, Chatelain B et al. Dabigatran: Safety, usefulness and practical details of drug monitoring. Dans Journal of Thrombosis and Haemostasis. 2011 Jul;9 Suppl 2:1-1055. 2011

Mullier F, Douxfils J, Robert S, Devel P, Chatelain C, Chatelain B et al.. Dabigatran: Safety, usefulness and practical details of drug monitoring.. 2011. Poster présenté à XXIII Congress of the International Society of Thrombosis and Haemostasis and 57th Annual SSC Metting, Kyoto, Japon.

Mullier F, Gheldof D, Robert S, Bailly N, Devel P, Doyen C et al. Implication of tissue-factor bearing microparticles in thrombosis associated with breast cancers. Dans Acta Clinica Belgica. Vol 66. 2011. p. 168-168

Mullier F, Douxfils J, Robert S, Devel P, Chatelain C, Chatelain B et al. Rivaroxaban: safety, usefulness and practical details of drug monitoring. Dans J Thromb Haemost. 2011 Jul;9 Suppl 2:1-1055. 2011

Mullier F, Douxfils J, Robert S, Devel P, Chatelain C, Chatelain B et al.. Rivaroxaban: safety, usefulness and practical details of drug monitoring. 2011. Poster présenté à XXIII Congress of the International Society of Thrombosis and Haemostasis and 57th Annual SSC Metting, Kyoto, Japon.

2010

Mullier F, Bailly N, Cornet Y, Dubuc E, Robert S, Osselaer J-C et al. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. Thrombosis and Haemostasis. 2010 juin;103(6):1277-81. https://doi.org/10.1160/TH09-10-0711

Robert S, Baccelli C, Devel P, Dogné J-M, Quetin-Leclercq J. Effects of leaf extracts from Croton zambesicus Müell. Arg. on hemostasis. Journal of Ethnopharmacology. 2010 avr. 21;128(3):641-8. https://doi.org/10.1016/j.jep.2010.02.007

Mullier F, Bailly N, Dogné J-M, Chatelain B. A survey of last generation FCM performances to study microparticles. Dans 56th Annual Scientific and StandardizationCommittee Meeting (SSC) of the International Society of Thrombosis and Hemostasis (ISTH), Cairo. 2010

Robert S, Mullier F, Mekouar H, Polet F, Douxfils J, Biot F et al. Comparison of Laboratory Assays to Measure Rivaroxaban and Dabigatran. Dans Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3332. . 2010

Robert S, Mullier F, Mekouar H, Polet F, Douxfils J, Biot F et al.. Comparison of Laboratory Assays to Measure Rivaroxaban and Dabigatran. 2010. Poster présenté à 52nd ASH Annual Meeting and Exposition, Belgique.

Mullier F, Bailly N, Cornet Y, Robert S, Dubuc E, Osselaer J-C et al. Contribution of Platelet Microparticles Generation Assay to the Diagnosis of Type II Heparin-induced Thrombocytopenia. Thrombosis and Haemostasis. 2010;103(6):1277-1281.

Robert S, Mullier F, Lufin N, Devel P, Chatelain B, Dogne J-M. Evaluation of Anticoagulant Drugs with TF-Induced Thrombin Generation: An In Vitro comparative Study In Platelet-Rich Plasma (PRP) Versus Platelet-Poor Plasma (PPP). Dans BLOOD. Vol 116. 2010. p. 1365-1366

Mullier F, Bailly N, Dogné J-M, Chatelain B. HOW TO MEASURE PLATELET MICROPARTICLES BYFLOW CYTOMETRY? PRINCIPLES AND COMPARISON OF INSTRUMENT PERFORMANCES. Belgian Society of Clinical Biology, Anvers, October 16th; 2010. 2010.

Mullier F, Dogne J-M, Bailly N, Gheldof D, Cornet Y, Chatelain B. HOW TO MEASURE PLATELET MICROPARTICLES BY FLOW CYTOMETRY? PRINCIPLES AND COMPARISONS OF INSTRUMENT PERFORMANCES. Dans CYTOMETRY PART B-CLINICAL CYTOMETRY. Vol 78. 2010. p. 424-425

Mullier F, Gheldof D, Robert S, Bailly N, Devel P, Michiels C et al. Implication of tissue-factor bearing microparticles in thrombosis associated with breast cancer. Belgian Society of Clinical Biology, Anvers,October 16th; 2010. 2010.

Mullier F, Gheldof D, Robert S, Bailly N, Devel P, Doyen C et al. Implication of Tissue-Factor Bearing Microparticles In Thrombosis Associated with Breast Cancer. Dans CYTOMETRY PART B-CLINICAL



CYTOMETRY. Vol 78. 2010. p. 458-458

Mullier F, Bailly N, Dogné J-M, Chatelain B. Introduction to microparticles: 2010 and future. Dans Sta user's meeting, Paris. 2010

Mullier F, Robert S, Devel P, Alpan L, Lufin N, Chatelain B et al. Pharmacological Study of Antimyeloma Agents on Hemostasis. Dans BLOOD. Vol 116. 2010. p. 1305-1305

Mullier F, Bailly N, Cornet Y, Robert S, Osselaer J-C, Chatelain C et al. Platelet Microparticle Generation Assay: a valuable and simpler alternative to 14C-SRA for type-II HIT diagnosis. Belgian Society of Clinical Biology, Anvers, October 16th; 2010. 2010.

Mullier F, Dogné J-M, Bailly N, Cornet Y, Robert S, Chatelain B. Study of small particles by flow cytometry: Present and future. Dans Abstract Book International Society for Analytical Cytology (ISAC 2010), Seattle. 2010

Laloy J, Robert S, Marbehant C, Mullier F, Mejia Mendoza JH, Piret J-P et al. The calibrated thrombin generation test (cTGT) : a gold standard assay to assess the procoagulant activity of nanomaterials. 50) NARILIS symposium. Faculté de Médecine. FUNDP Namur. October 23th, 2010. 2010.

Robert S, Decrem Y, Rath G, Dessy C, Feron O, Mullier F et al. The tick protein Ir-CPI efficiently delays contact pathway induced thrombin generation and displays in vivo antithrombotic activity. 49) NARILIS symposium. Faculté de Médecine. FUNDP Namur. October 23th, 2010. 2010.

Mullier F, Lainey E, Fenneteau O, Da Costa LM, Schillinger F, Bailly N et al. Usefulness of microparticles's Release to Improve Diagnosis of Hereditary Spherocytosis: Results of a Multicentre Study. Dans BLOOD. Vol 116. 2010. p. 847-848

2009

Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. Journal of Experimental Medicine. 2009 oct. 26;206(11):2381-2395. https://doi.org/10.1084/jem.20091007

Praticò D, Dogné J-M. Vascular biology of eicosanoids and atherogenesis. Expert Review of Cardiovascular Therapy. 2009 sept.;7(9):1079-89. https://doi.org/10.1586/erc.09.91

Thiry A, Delayen A, Goossens L, Houssin R, Ledecq M, Frankart A et al. Synthesis and biological evaluation of a new family of anti-benzylanilinosulfonamides as CA IX inhibitors. European Journal of Medicinal Chemistry. 2009 févr. 1;44(2):511-8. https://doi.org/10.1016/j.ejmech.2008.03.034

Mullier F, Dogné J-M, Bailly N, Cornet Y, Robert S, Chatelain B. Accurate quantification of microparticles by flow cytometry: important issues. Journal of Thrombosis and Haemostasis. 2009;7(2).

Mullier F, Dogné J-M, Chatelain B. A novel algorithm to improve diagnosis of hereditary spherocytosis.Dans Focus Diagnostica 2009. 2009

Mullier F, Bailly N, Cornet Y, Dogné J-M, Chatelain B. A novel concept to improve diagnosis of Hereditary Spherocytosis. Abstract Book-Société Belge Biologie Clinique 2009. 2009.

Mullier F, Dogné J-M, Chatelain B. Application of the case manager concept to the diagnosis of hereditary spherocytosis. Dans Sysmex European Haematology Symposium 2009, Istanbul (Turkey). 2009

Thiry A, Dogné J-M, Masereel B. Conception et synthèse d'indanesulfonamides en tant qu'inhibiteurs originaux des anhydrases carboniques. Chimie nouvelle. 2009;(100):22-25.

Mullier F, Daliphard S, Garand R, Dekeyser M, Cornet Y, Luquet I et al. Cytologie des syndromes myélodysplasiques avec ider(20q). Dans Groupe Français d'Hématologie Cellulaire (GFHC) 2009 Bruxelles. 2009

Thiry A, Dogné J-M, Supuran C, Masereel B. Drug design of carbonic anhydrase inhibitors as anticonvulsant agents. Dans Claudiu T, Jean-Yves S, rédacteurs en chef, Drug-Design of Zinc-Enzyme inhibitors: Functional, Structural, and Disease Applications. Hoboken, New-Jersey: John Wiley & Sons. 2009. p. 171-191

Dogné J-M, Thiry A, Masereel B, Supuran C. Dual carbonic anhydrase and cyclooxygenase-2 inhibition. Dans Claudiu T, Jean-Yves S, rédacteurs en chef, Drug Design of zinc-enzyme inhibitors: Functional, Structural, and Disease Applications. Hoboken, New-Jersey, USA: John Wiley and Sons. 2009. p. 255-272

Robert S, Baccelli C, Devel P, Dogné J-M, Quetin-Leclercq J. Effects of leaf extracts from Croton zambesicus on hemostasis. Dans Abstract book - 23èmes Journées Franco-Belges de Pharmacochimie. 2009

Delanaye P, Janssen N, Dogné J-M, Dubois B, Ghuysen A, Kolh P et al. Influence de la largeur des



pores des membranes utilisées au cours de l’hémofiltration et du débit d’ultrafiltration sur la clairance plasmatique de l’interleukine 6 dans un modèle porcin de choc septique. Réanimation. 2009;18(1).

Robert S, Ghiotto J, Pirotte B, David J-L, Masereel B, Pochet L et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs ? Dans Abstract book - Annual Meeting of Belgian Society on Thrombosis and Haemostasis. 2009

Robert S, Ghiotto J, Pirotte B, David J-L, Masereel B, Pochet L et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacological Research. 2009;59(3):160-166.

Mullier F, Bailly N, Dogné J-M, Chatelain B. Platelet microparticles quantification. Dans Abstract Book-European Society of Clinical Cell Analysis (ESCCA) 2009 . 2009

Mullier F, Dogné J-M, Chatelain B. Platelets and microparticles. Dans Molecular Biology and Cytometry Course, ABCA/BVAC 2009. 2009

Laloy J, Marbehant C, Robert S, Mullier F, Chatelain B, Dogné J-M et al. Potential nanotoxicity in blood : Effects of engineered nanoparticles on human blood constituents. Nanofac 2009. 2009.

2008

Thiry A, Rolin S, Vullo D, Frankart A, Scozzafava A, Dogne J-M et al. Indanesulfonamides as carbonicanhydrase inhibitors and anticonvulsant agents: Structure-activity relationship and pharmacological evaluation. European Journal of Medicinal Chemistry. 2008 déc. 1;43(12):2853-2860. https://doi.org/10.1016/j.ejmech.2008.02.018

Thiry A, Supuran CT, Masereel B, Dogné JM. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. Journal of Medicinal Chemistry. 2008 juin 12;51(11):3051-3056. https://doi.org/10.1021/jm701526d

Thiry A, Dogné J-M, Supuran CT, Masereel B. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Current Pharmaceutical Design. 2008;14(7):661-71.

Dogné J-M, Thiry A, Supuran CT. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs. Current Pharmaceutical Design. 2008;14(7):679-84.

Dogné J-M, Thiry A, SUPURAN CT. Carbonic anhydrase inhibition insight into non-COX2 pharmacological effect of some coxibs. Current Pharmaceutical Design. 2008;14(7):679-684.

D'ambrosio K, Vitale R-M, Dogné J-M, Masereel B, Innocenti A, Scozzafava A et al. Carbonic anhydrase inhibitors: Bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. Journal of Medicinal Chemistry. 2008;51(11):3230-3237.

Hanson J, Dogne JM, Ghiotto J, Neven P, Kelley LP, Kinsella BT et al. Characterization of Original TP receptor antagonists presenting differential activity on alpha and beta isoforms. Dans FUNDAMENTALCLINICAL PHARMACOLOGY. Vol 22. 2008. p. 225-225

Mullier F, Bailly N, Cornet Y, Robert S, Dogné J-M, Chatelain B. Contribution of platelet microparticles assay to type II HIT. Dans Abstract Book-Association Belge de Cytologie Analytique 2008 (ABCA/BVAC). 2008

Robert S, Bertolla C, Masereel B, Dogné J-M, Pochet L. Design, synthesis and pharmacological evaluation of novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. Dans Abstract book - Small Molecules, Antibodies and Natural Products: Multiple Faces of Medicinal Chemistry. 2008

Mullier F, Bailly N, Dogné J-M, Chatelain B. High-speed cell sorting. Dans BD sorter User's meeting 2008. 2008

Dogne J-M, Rolin S, Kempen HJ. Naftidrofuryl is an effective antagonist of vascular smooth muscle contraction induced by oxidative stress mediator 8-iso-PGF (2 alpha). Dans ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. Vol 28. 2008. p. E142-E143

Robert S, Bertolla C, Masereel B, Dogné J-M, Pochet L. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. Journal of Medicinal Chemistry. 2008;51:3077-3081.

Robert S, Bertolla C, Masereel B, Dogné J-M, Pochet L. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. Drugs of the future. 2008;33(suppl A).

Robert S, Frédérick R, Masereel B, Dogné J-M, Pochet L. Pharmacological evaluation of 6-chloromethyl-coumarins bearing a basic moeity in the 3-position as new anticoagulants drugs. Chimie nouvelle. 2008;98:26-26.

Michaux C, Robert S, Del Tedesco M, Masereel B, Dogné J-M, Pochet L. Structural insights into the inhibition mode of the activated coagulation factor XII by coumarins. Drugs of the future. 2008;33(suppl A).



Thiry A, Ledecq M, Dogné J-M, Supuran C, Wouters J, Masereel B. Towards new leads for selective carbonic anhydrase IX inhibition: synthesis, pharmacologcal evaluation and combined ligand-based and target-based approach. Chimie nouvelle. 2008;98:26-26.

2007

Thiry A, Masereel B, Dogne J-M, Supuran CT, Wouters J, Michaux C. Exploration of the binding modeof indanesulfonamides as selective inhibitors of human carbonic anhydrase type VII by targeting Lys91. ChemMedChem. 2007 sept. 10;2(9):1273-1280. https://doi.org/10.1002/cmdc.200700057

Hanson J, Dogné J-M, Ghiotto J, Moray A-L, Kinsella BT, Pirotte B. Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor. Journal of Medicinal Chemistry. 2007 août 9;50(16):3928-36. https://doi.org/10.1021/jm070427h

Rolin S, Hanson J, Vastersaegher C, Cherdon C, Pratico D, Masereel B et al. BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents. Prostaglandinsand Other Lipid Mediators. 2007 août;84(1-2):14-23. https://doi.org/10.1016/j.prostaglandins.2007.03.002

Dogné JM, Thiry A, Practico D, Masereel B, Supuran CT. Dual carbonic anhydrates - Cyclooxygenase-2 inhibitors. Current Topics in Medicinal Chemistry. 2007 mai 1;7(9):885-891. https://doi.org/10.2174/156802607780636717

Cyrus T, Yao Y, Ding T, Dogne J-M, Praticò D. A novel thromboxane receptor antagonist and synthaseinhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. European Journal of Pharmacology. 2007 avr. 30;561(1-3):105-11. https://doi.org/10.1016/j.ejphar.2006.12.024

Cyrus T, Yao Y, Ding T, Dogne J-M, Praticò D. Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood. 2007 avr. 15;109(8):3291-6. https://doi.org/10.1182/blood-2006-08-044990

Lanoye L, Segers P, Tchana-Sato V, Rolin S, Dogne J-M, Ghuysen A et al. Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion. Experimental Physiology. 2007 janv.;92(1):127-37. https://doi.org/10.1113/expphysiol.2006.034983

Jaspart S, Bertholet P, Piel G, Dogné J-M, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V. 2007 janv.;65(1):47-56. https://doi.org/10.1016/j.ejpb.2006.07.006

Kolh PH, Tchana-Sato V, Ghuysen A, Lambermont B, Rolin S, D'orio V et al. 357 Comparative effects on LV performance, arterial hemodynamics and ventriculo-arterial coupling of two models of coronary artery occlusion in pigs. European Journal of Heart Failure Supplements. 2007;6(Suppl):82-82.

Cherdon C, Rolin S, Hanson J, Drion PV, De Leval L, Defraigne J-O et al. BM-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apo E-deficient mice. Journal of Molecular and Cellular Cardiology . 2007;42(6):S33-S34.

Thiry A, Dogné J-M, Supuran CT, Masereel B. Carbonic anhydrase inhibitors as anticonvulsant agents. Current Topics in Medicinal Chemistry. 2007;7(9):855-864.

Winum J-Y, Thiry A, El Cheikh K, Dogné J-M, Montero J-L, Vullo D et al. Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorganic and medicinal chemistry letters. 2007;17(10):2685-2691.

Thiry A, Ledecq M, Dogné J-M, SUPURAN CT, Wouters J, Masereel B. Carbonic anhydrase inhibitors: synthesis, biological evaluation and rational drug design to target the tumor-associated CA IX. Dans Abstract Book-13th Belgian Forum of Pharmaceutical Sciences. 2007

Lanoye L, Segers P, Tchana-Sato V, Rolin S, Dogné J-M, Ghuysen A et al. Cardiovascular Hemodynamics and Ventriculo-Arterial Coupling in an Acute Pig Model of Ischemia-Reperfusion. Experimental Physiology. 2007;92(1):127-137.

Dogné J-M, Thiry A, Pratico D, Masereel B, Supuran CT. Dual carbonic anhydrase - Cyclooxygenase-2 inhibitors. Current Topics in Medicinal Chemistry. 2007;7(9):885-891.

Robert S, Dogné J-M. Exercices de Technologie Pharmaceutique. 2007.

Kolh P, Tchana-Sato V, Ghuysen A, Lambermont B, Desaive T, Rolin S et al. Hemodynamic evaluation of two models of coronary artery occlusion in pigs. Acta Cardiologica. 2007.

Thiry A, Frankart A, Michaux C, Dogné J-M, SUPURAN CT, Wouters J et al. Inhibiteurs d'anhydrases carboniques. Evaluation de l'effet anticonvulsivant d'indanesulfonamides. Dans Abstract Book-



21èmes Journées Franco-Belges de Pharmacochimie. 2007

Cherdon C, Rolin S, Hanson J, Drion P-V, de Leval L, Defraigne J-O et al. Le BM-573, un antagoniste original de récepteur au thromboxane A2, réduit le développement des lésions athéromateuses chez des souris déficientes en apolipoprotéine E (Apo E-/-). Dans Abstract book - XXIèmes Journées franco-belges de pharmacochimie. 2007

Robert S, Ghiotto J, Pirotte B, David J-L, Masereel B, Pochet L et al. Le profil d'activité de thrombine: un puissant test de criblage ex vivo pour le développement d'agents anticoagulants. Dans Abstract Book-21èmes Journées Franco-Belges de Pharmacochimie. 2007

Robert S, Bertolla C, Masereel B, Dogné J-M, Pochet L. Nouvelles coumarines 3-carboxamides en tant qu'inhibiteurs de facteur XIIa. Dans Abstract Book-21èmes Journées Franco-Belges de Pharmacochimie. 2007

Robert S, Frédérick R, Masereel B, Dogné J-M, Pochet L. Pharmacological evaluation of 6-chloromethyl-coumarins bearing a basic moiety in the 3-position as new anticoagulant drugs. Dans Abstract Book-New Drugs and Drug Candidates: Recent Achievements in Medicinal Chemistry. 2007

Robert S, Ghiotto J, Pirotte B, David J-L, Masereel B, Pochet L et al. Thrombin activity profile: a powerful ex vivo screening test for the development of anticoagulant drugs. Journal of Thrombosis and Haemostasis. 2007;5(Suppl. 2).

Robert S, Ghiotto J, Pirotte B, David J-L, Masereel B, Pochet L et al. Thrombin activity profile: a powerful ex vivo screening test for the development of anticoagulant drugs. Dans Abstract Book-XXIstCongress of the International Society on Thrombosis and Haemostasis. 2007

Robert S, Ghiotto J, Pirotte B, David J-L, Masereel B, Pochet L et al. Thrombin activity profile: a rapid, reliable and relevant ex vivo screening test for the development of anticoagulant drugs. Dans Abstract Book-13th Belgian Forum of Pharmaceutical Sciences. 2007

Thiry A, Ledecq M, Dogné J-M, SUPURAB CT, Wouters J, Masereel B. Towards new leads for selective carbonic anhydrase IX inhibition: synthesis, pharmacological evaluation and combined ligand-based and target-based approach. Dans Abstract Book-New Drugs and Drug Candidates : Recent Achievements in Medicinal Chemistry. 2007

2006

Delanaye P, Lambermont B, Dogné J-M, Dubois B, Ghuysen A, Janssen N et al. Confirmation of high cytokine clearance by hemofiltration with a cellulose triacetate membrane with large pores: an in vivo study. The International journal of artificial organs. 2006 oct.;29(10):944-8.

de Leval X, Dassesse T, Dogné J-M, Waltregny D, Bellahcène A, Benoit V et al. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. The Journal of pharmacology and experimental therapeutics. 2006 sept.;318(3):1057-67. https://doi.org/10.1124/jpet.106.101188

Lambermont B, Delanaye P, Dogné J-M, Ghuysen A, Janssen N, Dubois B et al. Large-pore membrane hemofiltration increases cytokine clearance and improves right ventricular-vascular coupling during endotoxic shock in pigs. Artificial organs. 2006 juil.;30(7):560-4. https://doi.org/10.1111/j.1525-1594.2006.00260.x

Hanson J, Reynaud D, Qiao N, Devel P, Moray A-L, Renard J-F et al. Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor. Journal of Medicinal Chemistry. 2006 juin 15;49(12):3701-9. https://doi.org/10.1021/jm060108a

Thiry A, Ledecq M, Cecchi A, Dogne J-M, Wouters J, Supuran CT et al. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. Journal of Medicinal Chemistry. 2006 mai 4;49(9):2743-2749. https://doi.org/10.1021/jm0600287

Kolh P, Rolin S, Tchana-Sato V, Pétein M, Ghuysen A, Lambermont B et al. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Prostaglandins and Other Lipid Mediators. 2006 mars;79(1-2):53-73. https://doi.org/10.1016/j.prostaglandins.2005.10.002

Delanaye P, Lambermont B, Dogne JM, Dubois B, Ghuysen A, Janssen N et al. Artificial Kidney and Dialysis-Confirmation of high cytokine clearance by hemofiltration with a cellulose triacetate membrane with large pores: An in vivo study. The International journal of artificial organs. 2006;29(10):944-948.

Delanaye P, Lambermont B, Dogné J-M, Dubois B, Ghuysen A, Janssen N et al. Clairance plasmatique des cytokines IL6 et IL10 par hémofiltration avec un filtre à larges pores dans un modèle porcin de choc septique. Réanimation. 2006;15(S1).

Kolh P, Tchana-Sato V, Ghuysen A, Lambermont B, D'Orio V, Limet R et al. Comparative effects of left



ventricular performance, arterial hemodynamics, and left ventriculo-arterial (VA) coupling of two models of coronary artery occlusion in pigs. Journal of Biomechanics. 2006;39:S285.

Kolh P, Tchana-Sato V, Ghuysen A, Lambermont B, D'Orio V, Limet R et al. Comparative effects on LVperformance, arterial hemodynamics, and left ventriculo-arterial coupling of two models of coronary artery occlusion in pigs. CSDS 2006. 2006.

Dogné J-M, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. Current Pharmaceutical Design. 2006;12(8):971-5.

Thiry A, Ledecq M, Cecchi A, Dogné J-M, Wouters J, Supuran CT et al. Design, synthesis and biological evaluation of indanesulfonamides as carbonic anhydrase IX inhibitors. Fundamental and Clinical Pharmacology. 2006;20.

Desaive T, Janssen N, Péters F, Ghuysen A, Lambermont B, Pierard L et al. Dynamics of spontaneous ventricular fibrillation in acutely ischemic pigs. Europace: European Pacing, Arrhythmias,and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2006;8.

Dogne J-M, Ruan K-H. Editorial (Hot Topic: Latest Developments in Pharmaceutical Design of Arachidonic Acid Metabolites: Prostaglandins, Thromboxanes, Hepoxilins and Isoprostanes (Executive Editors: J.-M. Dogne and K.-H. Current Pharmaceutical Design. 2006;12(8):893-894.

Dogné J-M, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P et al. From the design to the clinical application of thromboxane modulators. Current Pharmaceutical Design. 2006;12(8):903-23.

Ruan K-H, Dogné J-M. Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs. Current Pharmaceutical Design. 2006;12(8):925-41.

Thiry A, Ledecq M, Cecchi A, Dogné J-M, Wouters J, Supuran CT et al. Indanesulfonamides as carbonic anhydrase inhibitors. Drugs of the future. 2006;31(A).

Hanson J, Dogne J-M, Moray A-L, Ghiotto J, Kelley LP, Kinsella BT et al. Pharmacological evaluation of TP receptor antagonists on alpha and beta receptor isoforms. Dans ACTA PHARMACOLOGICA SINICA. Vol 27. 2006. p. 21-21

Rolin S, Masereel B, Dogné J-M. Prostanoid as pharmacological targets in COPD and asthma. European Journal of Pharmacology. 2006;533:89-100.

Robert S, Rolin S, Dogné J-M. Séminaires de Biochimie Humaine. 2006.

Thiry A, Dogné J-M, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends in Pharmacological Sciences. 2006;27(11):566-573.

Cherdon C, Rolin S, Hanson J, de Leval L, Drion P-V, Pincemail J et al. The use of an apoE-deficient (apoE-/-) mice model to charaterize the therapeutic benefits of original thromboxane modulators. . Dans Abstract book - Bioforum. 2006

2005

Tchana-Sato V, Dogné J-M, Lambermont B, Ghuysen A, Magis D, Morimont P et al. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Prostaglandins and Other Lipid Mediators. 2005 déc.;78(1-4):82-95. https://doi.org/10.1016/j.prostaglandins.2005.04.001

Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM et al. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. The Journal of pharmacology and experimental therapeutics. 2005 avr.;313(1):293-301. https://doi.org/10.1124/jpet.104.079301

Winum J-Y, Dogné J-M, Casini A, De Leval X, Montero J-L, Scozzafava A et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. Journal of Medicinal Chemistry. 2005 mars 24;48(6):2121-5. https://doi.org/10.1021/jm0494826

Kolh P, Lambermont B, Ghuysen A, Tchana-Sato V, Dogne J-M, Hanson J et al. Effects of dobutamineon left ventriculoarterial coupling and mechanical efficiency in acutely ischemic pigs. Journal of cardiovascular pharmacology. 2005 févr.;45(2):144-52.

Dogne JM, Rolin S, Tchana-Sato V, Petein M, Ghuysen A, Lambermont B et al. 69 Characterization ofan original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig. European Journal of Heart Failure Supplements. 2005;4(Suppl):13-14.

Dogné J-M, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. Journal of Medicinal Chemistry. 2005;48(7):2251-2257.

Dogné J-M, Rolin S, Tchana-Sato V, Petein M, Ghuysen A, Lambermont B et al. A model of porcine



myocardial-infarction induced by progressive coronary-artery thromobosis provoked by ferric-chlorade. Hypertension. 2005;46:911-911.

Kolh P, Rolin S, Sato V, Petein M, Ghuysen A, Lambermont B et al. BM-573, a thromboxane A2 modulator, fails to prevent reperfusion injury in acutely ischemic pigs. Journal of Molecular and CellularCardiology . 2005;39:1035.

Dogné J-M, Rolin S, Petein M, Lambermont B, Hanson J, Dorio V et al. Characterisation of an originalmodel of myocardial-infarction provoked by coronary-artery thrombosis anduced by ferric-chloride in pigs. Journal of Molecular and Cellular Cardiology . 2005;38(6):104-104.

Dogné J-M, Rolin S, Pétein M, Tchana-Sato V, Ghuysen A, Lambermont B et al. Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig. Thrombosis Research. 2005;116(5):431-42. https://doi.org/10.1016/j.thromres.2005.02.006

Leemans J, Kirschvink N, Delvaux F, Cambier C, Jaspart S, Evrard B et al. Comparison of bronchodilators in feline airways: In vitro and in vivo investigations. In proceedings: 15th Congress European College of Veterinary Internal Medicine--companion animals. 2005.

Lanoye L, Kolh P, Rolin S, Tchana-Sato V, Dogné J-M, Ghuysen A et al. Effects of reperfusion on left ventricular hemodynamics and ventriculo-arterial coupling in acutely ischemic pigs. Computer Methods in Biomechanics and Biomedical Engeineering. 2005;8:169-170.

Desaive T, Janssen N, Péters F, Ghuysen A, Lambermont B, Pierard L et al. Electrical mapping of spontaneous ventricular fibrillation in acutely ischemic pigs. Proceedings of the 5th Belgian Day on Biomedical Engineering, 2005, Brussels. 2005.

Leemans J, Kirschvink N, Delvaux F, Jaspart S, Evrard B, Delattre L et al. In vitro and in vivo effects of salbutamol acetonide on cat airways. Proceedings: Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques. 2005.

Leemans J, Kirschvink N, Delvaux F, Cambier C, Evrard B, Delattre L et al. In vitro pharmacological activity of salbutamol acetonide on the isolated guinea-pig trachea and porcine bronchus. Fundamental and Clinical Pharmacology. 2005;19.

Pratico D, Dogné J-M. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine.Circulation. 2005;112(7):1073-9.

Dogné J-M, Hanson J, Pratico D. Thromboxane, Prostacyclin and isoprostanes - Therapeutic targets in Atherogenesis. Trends in Pharmacological Sciences. 2005;26(12):639-644.

2004

Julémont F, de Leval X, Michaux C, Renard J-F, Winum J-Y, Montero J-L et al. Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. Journal of Medicinal Chemistry. 2004 déc. 30;47(27):6749-59. https://doi.org/10.1021/jm049480l

Mouithys-Mickalad A, Deby-Dupont G, Dogne J-M, de Leval X, Kohnen S, Navet R et al. Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1). Biochemical and Biophysical Research Communications. 2004 déc. 24;325(4):1122-30. https://doi.org/10.1016/j.bbrc.2004.10.155

Delarge J, Dogne J-M, Masereel B. Benzolsulfonamid-derivate und ihre verwendung Benzenesulfonamide derivatives and their use. 2004.

Rolin S, Dogne JM, Vastersaegher C, Hanson J, Masereel B. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors. Prostaglandins & Other Lipid Mediators. 2004 oct.;74(1-4):75-86.

Lambermont B, Segers P, Ghuysen A, Tchana-Sato V, Morimont P, Dogne J-M et al. Comparison between single-beat and multiple-beat methods for estimation of right ventricular contractility. Critical care medicine. 2004 sept.;32(9):1886-90.

Kolh P, Lambermont B, Ghuysen A, Tchana-Sato V, Dogné J-M, D'Orio V et al. Comparison of the effects of propofol and pentobarbital on left ventricular adaptation to an increased afterload. Journal of cardiovascular pharmacology. 2004 sept.;44(3):294-301.

Ghuysen A, Lambermont B, Dogné J-M, Kolh P, Tchana-Sato V, Morimont P et al. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. The Journal of pharmacology and experimental therapeutics. 2004 sept.;310(3):964-72. https://doi.org/10.1124/jpet.104.066852

Dogné JM, de Leval X. Preface. Mini-reviews in medicinal chemistry. 2004 août 1;4(6).

de Leval X, Julémont F, Benoit V, Frederich M, Pirotte B, Dogné J-M. First and second generations of



COX-2 selective inhibitors. Mini-reviews in medicinal chemistry. 2004 août;4(6):597-601.

Julémont F, Dogné J-M, Pirotte B, de Leval X. Recent development in the field of dual COX / 5-LOX inhibitors. Mini-reviews in medicinal chemistry. 2004 août;4(6):633-8.

de Leval X, Ilies M, Casini A, Dogné J-M, Scozzafava A, Masini E et al. Carbonic anhydrase inhibitors:synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity. Journal of Medicinal Chemistry. 2004 mai 20;47(11):2796-804. https://doi.org/10.1021/jm031116j

de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogné JM. New developments on thromboxane and prostacyclin modulators part 1: Prostacyclin modulators. Current Medicinal Chemistry. 2004 mai 1;11(10):1243-1252.

Dogné J-M, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Current Medicinal Chemistry. 2004 mai;11(10):1223-41.

Dogné J-M, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L et al. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. The Journal of pharmacology and experimental therapeutics. 2004 mai;309(2):498-505. https://doi.org/10.1124/jpet.103.063610

Hanson J, de Leval X, David J-L, Supuran C, Pirotte B, Dogné J-M. Progress in the field of GPIIb/IIIa antagonists. Current medicinal chemistry. Cardiovascular and hematological agents. 2004 avr.;2(2):157-67.

Roland I, de Leval X, Evrard B, Pirotte B, Dogné JM, Delattre L. Modulation of the arachidonic cascade with ω3 fatty acids or analogues: Potential therapeutic benefits. Mini-reviews in medicinal chemistry. 2004 janv. 1;4(6):659-668. https://doi.org/10.2174/1389557043403738

Lambermont B, Kolh P, Ghuysen A, Segers P, Dogné J-M, Tchana-Sato V et al. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Shock (Augusta, Ga.). 2004 janv.;21(1):45-51. https://doi.org/10.1097/01.shk.0000095935.86703.ca

Kolh P, Lambermont B, Ghuysen A, Tchana-Sato V, Morimont P, Dogné JM et al. 492 Effects of dobutamine on ventriculo-arterial coupling and mechanical efficiency in ischaemic pigs. European Journal of Heart Failure Supplements. 2004;3(Suppl):126-126.

Dogne JM, de Leval X. Arachidonic acid cascade modulators: The cyclooxygenase pathway-Preface. 2004.

Hanson J, Rolin S, De Leval X, Neven P, Masereel B, Pirotte B et al. Characterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonist. Fundamental and Clinical Pharmacology. 2004.

Rolin S, Pétein M, Dogné J-M, Michaux C, Vastershaeger C, Masereel B. Conception, synthèse et évaluation pharmacologique d'une sulfonylurée nitrobenzénique originale modulatrice de la voie du TXA2 en tant qu'agent anti-asthmatique potentiel. Dans Abstract book - XVIIIèmes Journées franco-belges de pharmacochimie. 2004

Vastersaegher C, Dogné J-M, Hanson J, Masereel B, Rolin S. Evaluation pharmacologique chez le cobaye d'une sulfonylurée originale (BM-520) apparentée au torasémide en tant qu'antagoniste du récepteur du TXA2. Dans Abstract book - XVIIIèmes journées franco-belges de pharmacochimie. 2004

Hanson J, Kolh P, Rolin S, Tchana-Sato V, De Leval X, Petein M et al. In vivo pharmacological evaluation of BM-573, an original thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. Fundamental and Clinical Pharmacology. 2004.

Roland I, d Leval X, Evrard B, Pirotte B, Dogne J-M, Delattre L. Modulation of the arachidonic cascadewith omega3 fatty acids or analogues: potential therapeutic benefits. Mini-reviews in medicinal chemistry. 2004;4(6):659-668.

Hanson J, Renard J-F, Rolin S, Neven P, de Leval X, Dogné J-M et al. Synthesis and pharmacologicalevaluation of original thromboxane A2 receptor antagonists derived from BM-573. Fundamental and Clinical Pharmacology. 2004;18:593-599.

2003

Segers P, Tchana-Sato V, Leather HA, Lambermont B, Ghuysen A, Dogne JM et al. Clinical value of preload-adjusted maximal power for the assessment of left ventricular contractility. Archives of Physiology and Biochemistry. 2003 sept. 1;111(SUPPL.).

Hanson J, de Leval X, Kolh P, Supuran C, Pirotte B, Dogné J-M. Update on GPIIb/IIIa antagonists. Expert Opinion on Therapeutic Patents. 2003 août 1;13(8):1173-1188.



https://doi.org/10.1517/13543776.13.8.1173

Michaux C, Dogne J-M, Rolin S, Masereel B, Wouters J, Durant F. A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors. European Journal of Medicinal Chemistry. 2003 juil. 1;38(7-8):703-710. https://doi.org/10.1016/S0223-5234(03)00076-X

Lambermont B, Ghuysen A, Dogné J-M, Kolh P, Tchana-Sato V, Morimont P et al. Effects of BM-573, a novel thromboxane A2 inhibitor, on pulmonary hemodynamics in endotoxic shock. Archives of Physiology and Biochemistry. 2003 juil.;111(3):224-31. https://doi.org/10.1076/apab.111.3.224.23457

Lambermont B, Kolh P, Dogné J-M, Ghuysen A, Tchana-Sato V, Morimont P et al. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitor. Archives of Physiology and Biochemistry. 2003 juil.;111(3):217-23. https://doi.org/10.1076/apab.111.3.217.23459

Kolh P, Lambermont B, Ghuysen A, D'Orio V, Gerard P, Morimont P et al. Alteration of left ventriculo-arterial coupling and mechanical efficiency during acute myocardial ischemia. International angiology :a journal of the International Union of Angiology. 2003 juin;22(2):148-58.

Segers P, Tchana-Sato V, Leather HA, Lambermont B, Ghuysen A, Dogne J-M et al. Determinants of left ventricular preload-adjusted maximal power. American Journal of Physiology-Heart and Circulatory Physiology. 2003 juin;284(6):H2295-301. https://doi.org/10.1152/ajpheart.01110.2002

DELARGE J, PIROTTE B, DOGNE J-M, de LEVAL X, JULEMONT F. PYRIDINIC SULFONAMIDE DERIVATIVES, METHOD OF PRODUCTION AND USE THEREOF. 2003.

Benoit P, Dogné J-M. Platelet ADP receptors and their antagonists. Mini-reviews in medicinal chemistry. 2003 mars;3(2):145-8.

De Leval X, Benoit V, Delarge J, Julémont F, Masereel B, Pirotte B et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. Prostaglandins Leukotrienes and Essential Fatty Acids. 2003 janv. 1;68(1):55-59. https://doi.org/10.1016/S0952-3278(02)00235-1

Julémont F, Dogné JM, Laeckmann D, Pirotte B, de Leval X. Recent developments in 5-lipoxygenase inhibitors. Expert Opinion on Therapeutic Patents. 2003 janv. 1;13(1):1-13. https://doi.org/10.1517/13543776.13.1.1

Dogné JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2003 janv.;68(1):49-54.

Ghuysen A, Lambermont B, Kolh P, Morimont P, Tchana-Sato V, Dogne J-M et al. 717 Haemodynamic effect of thromboxane A2 inhibition in acute pulmonary embolism. European Journal of Heart Failure Supplements. 2003;2(Suppl 1):150-151.

Rolin S, Pétein M, Tchana-Sato V, Dogné J-M, Lambermont B, Ghuysen A et al. A dual thromboxane inhibitor and thromboxane receptor antagonist prevents pig myocardial infarction induced by coronary thrombosis. Basic Research in Cardiology. 2003;98.

Rolin S, Petein M, Tchana-Sato V, Dogné J-M, Lambermont B, Ghuysen A et al. A dual thromboxane inhibitor and thromboxane receptor antagonist prevents pig myocardial infarction induced by coronary thrombosis. European Heart Journal. 2003;24(Suppl. S).

Dogné J-M, Kolh P, Rolin S, Tchana-Sato V, Hanson J, de Leval X et al. Antithrombotic activity of BM-573, a novel thromboxane modulator, in rat arterial thrombosis model, pig myocardial infarction model and its effects on bleeding time. Blood. 2003;(November suppl):4213.

Hanson J, Rolin S, de Leval X, Neven P, de Leval L, Masereel B et al. BM-613, a new thromboxane A2 antagonist, is characterized by a preferential activity on platelet thromboxane a2 receptors. Blood. 2003;November suppl(nÂ°3013).

Rolin S, Petein M, Dogné J-M, Tchana-Sato V, Kolh P, Masereel B. Effect of BM-573, a dual TXA2 synthase inhibitor and TXA2 receptor antagonist on infarct size in a porcine model of coronary thrombosis by ferric chloride. Pfllüg. Arch. - European Journal of Physiology. 2003;446:R4.

Rolin S, Dogné J-M, Pétein M, Delarge J, Masereel B. Effect of BM-573, a dual TXA2 synthase inhibitor and TXA2 receptor antagonist on infarct size in a porcine model of coronary thrombosis induced by ferric chloride. Dans Abstract book - Meeting de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques. 2003

Lambermont B, Ghuysen A, Kolh P, Tchana-Sato V, Segers P, Gérard P et al. Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovascular Research. 2003;59:412-418.

Ghuysen A, Lambermont B, Kolh P, Morimont B, Tchana-Sato V, Dogné J-M et al. Haemodynamic



effect of thromboxane A2 inhibition in acute pulmonary embolism. European Journal of Heart Failure. 2003;2(1).

Segers P, Tchana-Sato V, Leather HA, Lambermont B, Ghuysen A, Dogné J-M et al. Left ventricular preload-adjusted maximal power: Clinically useful marker of LV contractility? Circulation. 2003;108(17,Suppl. S).

De Leval X, Dassesse T, Benoit V, Pirotte B, David J-L, Merville M-P et al. Pharmacological evaluationof BM-573, a dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent. Blood. 2003.

de Leval X, Benoit P, Delarge J, Julémont F, Masereel B, Pirotte B et al. Pharmacological evaluation ofthe novel thromboxane modulator BM-567 (II/II): Effects of BM-567 on osteogenic sarcoma-cell-induced platelet agregation. Prostaglandins Leukotrienes and Essential Fatty Acids. 2003;68:55-59.

Julémont F, Dogné J-M, Laeckmann D, Pirotte B, Leval XD. Recent developments in 5lipoxygenase inhibitors. Expert Opinion on Therapeutic Patents. 2003;13(1):1-13.

2002

Michaux C, Dogné J-M, Norberg B, Durant F, Masereel B. N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition. Acta crystallographica. Section C: Crystal structure communications.2002 oct.;58:621-623.

Frédérich M, Dogné J-M, Angenot L, De Mol P. New trends in anti-malarial agents. Current Medicinal Chemistry. 2002 août;9(15):1435-56.

Leval XD, Julemont F, Delarge J, Pirotte B, Dogne J-M. New trends in dual 5-LOX/COX inhibition. Current Medicinal Chemistry. 2002 mai;9(9):941-62.

Michaux C, Charlier C, Julémont F, Dogné J-M, de Leval X, Norberg B et al. N-(3-Phenoxy-4-pyridinio)methanesulfonamidate. Acta crystallographica Section C: Crystal Structure communications.2002 févr.;58(Pt 2):o88-9.

Dogné J-M, de Leval X, Benoit P, Delarge J, Masereel B, David J-L. Recent advances in antiplatelet agents. Current Medicinal Chemistry. 2002 janv. 1;9(5):577-589.

Delarge J, Dogné J-M, Julémont F, Leval XD, Pirotte B, Sanna V. Advances in the field of COX-2 inhibition. Expert Opinion on Therapeutic Patents. 2002;12(7):969-989.

Dogné J-M, Benoit P, de Leval X, Rolin S, Neven P, Kolh P et al. Anti-platelet and antithrombotic properties of the nitrobenzenic sulfonylurea BM-573. Fundamental and Clinical Pharmacology. 2002;16:245.

Dogné J-M, Benoit P, de Leval X, Rolin S, Kolh P, Ghysen A et al. Antithrombotic properties of BM-573an original dual thromboxane receptor antagonist and thromboxane synthase inhibitor. Pathophysiology of Haemostasis and Thrombosis. 2002;32((S2)):60.

Dogné J-M, Leval XD, Pirotte B, Benoit P. Latest discoveries in prostaglandin receptor modulators. Expert Opinion on Therapeutic Patents. 2002;12(8):1225-1235.

2001

Rolin S, Dogné JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2001 août;65(2):67-72. https://doi.org/10.1054/plef.2001.0290

Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogné JM et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2001 août;50(8):391-9.

Dogné JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. Journal of Pharmacy and Pharmacology. 2001 mai 1;53(5):669-80. https://doi.org/10.1211/0022357011775992

Michaux C, Rolin S, Dogne J-M, Durant F, Masereel B, Delarge J et al. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition. Bioorganic & Medicinal Chemistry Letters. 2001 avr. 23;11(8):1019-1022. https://doi.org/10.1016/S0960-894X(01)00114-7

Dogné J-M, Benoit P, de Leval X, Neven P, Rolin S, Michaux C et al. Antiplatelet and antithrombotic properties of BM-573, a novel combined thromboxane receptor antagonist and thromboxane synthase inhibitor. Dans Abstract Book-XVèmes Journées Franco-Belges de Pharmacochimie. 2001.



p. 70

Rolin S, Dogné J-M, de Leval X, Delarge J, Masereel B. Biological evaluation of a novel sulfonylurea, BM-567, with a dual activity on thromboxane A2 synthase and receptor. Dans Abstract book - 10ème Forum de la Société Belge des Sciences Pharmaceutiques. 2001

Petit J, Vercauteren D, Dogné J-M, Durant F. Comparison of 3-D Physico-Chemical Properties of Ligands for the Thromboxane A2 Receptor Using the Kohonen Self-Organizing Maps Technique. Dans Abstracts of Papers of the American Chemical Society. Vol 221. 2001. p. COMP-210

Dogné J-M, de Leval X, Rolin S, Neven P, Kolh P, David J-L et al. Design and pharmacological evaluation of an original non-carboxylic thromboxane receptor antagonist and thromboxane synthase inhibitor as promising antiplatelet agent. Thrombosis and Haemostasis. 2001;(July suppl):P1630.

De Leval X, David J-L, Neven P, Benoit V, Pirotte B, Merville M-P et al. Effects of BM-573, a dual thromboxane A (2) receptor antagonist and thromboxane synthase inhibitor, on osteogenic sarcoma cell-induced platelet aggregation. Blood. 2001;98(11, Part 2).

de Leval X, Delarge J, Neven P, Michaux C, Masereel B, Pirotte B et al. Effects of thromboxane A2 receptor antagonists and COX inhibitors on osteogenic sarcoma cell-induced platelet aggregation. Dans Universitaires P, Namur D, rédacteurs en chef, Abstract Book-XVèmes Journées Franco-Belgesde Pharmacochimie.. 2001. p. 69

Rolin S, Dogné J-M, Delarge J, Masereel B. Pharmacological effect of BM-593, a novel sulfonylurea acting as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor on human platelets and isolated smooth muscles. Dans Universitaires P, Namur D, rédacteurs en chef, Abstract Book-XVèmes Journées Franco-Belges de Pharmacochimie. 2001. p. 78

Rolin S, Delarge J, Masereel B, Dogné J-M. Pharmacological effects of BM-593, a novel sulfonylurea acting as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor on human platelets and isolated smooth muscles. Dans Abstract book - XVèmes Journées franco-belges de pharmacochimie. 2001. p. 78

Dogné J-M, de Leval X, Benoit P, Neven P, de Leval L, Rolin S et al. Pharmacological evaluation of BM-573 an original dual thromboxane receptor antagonist and thromboxane synthase inhibitor as novel potent antithrombotic agent. Blood. 2001;december(suppl).

Rolin S, Dogné J-M, Delarge J, Masereel B. Pharmacological profile of BM-567, a novel thromboxaneA2 receptor antagonist and thromboxane A2 receptor antagonist and thromboxane A2 synthase inhibitor on the human platelets and isolated smooth muscles. Dans Abstract book - Meeting de la Société Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques. 2001

Rolin S, Dogné J-M, Delarge J, Masereel B. Pharmacological profile of BM-567, a novel thromboxaneA2 receptor antagonist and thromboxane A2 synthase inhibitor on the human platelets and isolated smooth muscle. Fundamental and Clinical Pharmacology. 2001;15:363.

Dogné J-M, de Leval X, Delarge J, Masereel B. Recent developments of thromboxane modulators. Expert Opinion on Therapeutic Patents. 2001;11:1663-1675.

Julémont F, de Leval X, Neven P, Devel P, Pirotte B, Delarge J et al. Synthèse et évaluation pharmacologique d'un méthanesulfonamide pyridinique apparenté à l'acide niflumique. Dans universitaires P, Namur D, rédacteurs en chef, Abstract Book-XVèmes Journées Franco-Belges de Pharmacochimie. 2001. p. 49

2000

Michaux C, Norberg B, Dogne J-M, Durant F, Masereel B, Delarge J et al. Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition. Acta crystallographica Section C: Crystal Structure communications. 2000 oct. 1;56(10):1265-1266. https://doi.org/10.1107/S0108270100009872

Wouters J, Michaux C, Durant F, Dogne J-M, Delarge J, Masereel B. Isosterism among analogues of torasemide: Conformational, electronic and lipophilic properties. European Journal of Medicinal Chemistry. 2000 oct.;35(10):923-929. https://doi.org/10.1016/S0223-5234(00)01174-0

de Leval X, Delarge J, Somers F, de Tullio P, Henrotin Y, Pirotte B et al. Recent advances in inducible cyclooxygenase (COX-2) inhibition. Current Medicinal Chemistry. 2000 oct.;7(10):1041-62.

DELARGE J, DOGNE J-M, MASEREEL B. Benzenic sulphonamide derivatives and their uses. 2000.

Dogné JM, de Leval X, Delarge J, David JL, Masereel B. New trends in thromboxane and prostacyclinmodulators. Current Medicinal Chemistry. 2000 juin;7(6):609-28.

Dogné JM, De Leval X, Neven P, Rolin S, Wouters J, Delarge J et al. Pharmacomodulation studies of torasemide leading to original non- carboxylic thromboxane A receptor antagonists. Pharmacy and pharmacology communications. 2000 févr. 1;6(2):77-82.

Somers F, De Tullio P, Boverie S, Dogné JM, De Leval X, Antoine M-H et al. Synthesis and biological



effects of new 3-alkylamino-4H-1,2,4- benzothiadiazine 1,1-dioxides on insulin-secreting cells. Pharmacy and pharmacology communications. 2000 févr. 1;6(2):89-95.

Boverie S, Somers F, Ouedraogo R, Antoine M-H, Dogne J-M, De Leval X et al. 7-Substituted alkylamino-4H-1, 2, 4-benzothiadiazine 1, 1-dioxides as new analogues of diazoxide: effects on the insulin releasing process in vitro. Fundamental and Clinical Pharmacology. 2000;14.

de Leval X, Delarge J, Rolin S, Masereel B, Dogne J-M. BM-144, a novel thromboxane A2 receptor antagonist relaxes trachea guinea pig in vitro. Journal of Allergy and Clinical Immunology. 2000;105(1):S21.

Rolin S, Dogné J-M, Delarge J, Masereel B. BM-531, a novel sulfonylurea acting as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. Dans Abstract book - XIVèmes Journées franco-belges de pharmacochimie. 2000

Rolin S, Dogné J-M, Delarge J, Masereel B. BM-573, a novel potent dual acting agent for thromboxane A2 receptor antagonism and thromboxane A2 synthase inhibition. Dans Abstract book-9ème Forum de la Société Belge des Sciences Pharmaceutiques. 2000

Dogné J-M, de Leval X, Neven P, Rolin S, David J-L, Delarge J et al. Characterization of the antiplatelet activity of ticlopidine and acetylsalicylic acid by PFA-100. Fundamental and Clinical Pharmacology. 2000;14:168.

Dogne J-M. Conception, synthèse et évaluation pharmacologique de dérivés originaux du torasémideà propriétés antagonistes du thromboxane A2 et inhibitrices de la thromboxane synthétase. 2000.

Dogné J-M, de Leval X, Rolin S, Neven P, Kolh P, David J-L et al. Design and pharmacological evaluation of a novel combined thromboxane A2 receptor antagonist and thromboxane synthase inhibitor derived from torasemide as promising antiplatelet agent. Blood. 2000;96(11):230.

Dogné J-M, de Leval X, Delarge J, Reginster J-Y, Henrottin Y, Neven P et al. Design, synthesis and pharmacological evalution of original thromboxane receptor antagonists. Mediators of Inflammation. 2000;9:53.

Dogné J-M, de Leval X, Neven P, Rolin S, Somers F, David J-L et al. Effects of TXA2 receptor antagonists derived from torasemide on platelet function. Fundamental and Clinical Pharmacology. 2000;14:168.

de Leval X, Henrotin Y, Masereel B, Somers F, Neven P, Devel P et al. Evaluation of classical NSAIDson COX-1 and COX-2 purified enzymes and prognosis of their effects on physiological responses. Fundamental and Clinical Pharmacology. 2000;14:167.

Kolh P, D'Orio V, Lambermont B, Gerard P, Gommes C, Dogné JM et al. Increased aortic compliance decreases the energetic cost of left ventricular ejection. European Journal of Heart Failure. 2000;2(S1):120-121.

Dogné J-M, de Leval X, Neven P, Somers F, Delarge J, Rolin S et al. Pharmacological evaluation of original sulfonylureas as thromboxane A2 antagonists. Fundamental and Clinical Pharmacology. 2000;14:300.

De Leval X, Dogne J-M, Masereel B, Pirotte B, Reginster J-Y, Neven P et al. Profile of nimesulide and nimesulide beta-cyclodextrin on chondrocyte metabolism. Fundamental and Clinical Pharmacology. 2000;14:169.

1999

De Tullio P, Ouedraogos R, Dupont L, Somers F, Boverie S, Dogné J-M et al. Synthesis and structural studies of 3-alkylamino-pyrido[4,3-e]-1,2,4- thiadiazine 1,1-dioxides: A new class of heterocyclic compounds with therapeutical promises. Tetrahedron. 1999 avr. 23;55(17):5419-5432. https://doi.org/10.1016/S0040-4020(99)00231-8

Lacan F, Varache-Lembège M, Vercauteren J, Léger J-M, Masereel B, Dogné J-M et al. Synthesis, structural characterization and thromboxane A receptor antagonistic activity of 3-substituted 2-[(arylsulfonyl)imino]-2,3- dihydrothiazolyl derivatives. European Journal of Medicinal Chemistry. 1999 avr. 1;34(4):311-328. https://doi.org/10.1016/S0223-5234(99)80082-8

Dogne JM, de Leval X, Delarge J, Neven P, Rolin S, David JL et al. Antiplatelet properties of BM-519, a novel combined thromboxane A (2) receptor antagonist and thromboxane synthase inhibitor. Dans BLOOD. Vol 94. 1999. p. 103B-103B

Dogné J-M, de Leval X, Delarge J, Neven P, Rolin S, David J-L et al. Antiplatelet properties of BM-519, a novel combined thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. Blood. 1999;94((suppl 1)):3625.

Dogné J-M, Neven P, Damas J, Fontaine J, Rolin S, de Leval X et al. BM 144: an original thromboxane A2 receptor antagonist derived from torasemide. Journal de Pharmacie de Belgique. 1999;54:57-58.



Masereel B, Lacan F, Fontaine J, Nuhrich A, Delarge J, Pochet L et al. BM-519, a novel non-carboxylic thromboxane A2 antagonist. Fundamental and Clinical Pharmacology. 1999;13((suppl 1)):191s.

de Leval X, Dogné JM, Neven P, Labasse A, Delarge J, Reginster JY et al. Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study. Journal de Pharmacie de Belgique. 1999;54(3):89-90.

De Leval X, Dogne JM, Neven P, Labasse A, Delarge J, Reginster J-Y et al. Effects of nimesulide and indomethacin on cyclooxygenaxse-1 and 2: a comparative study. Osteoarthritis and Cartilage. 1999;7(SA).

Rolin S, Dogné J-M, Neven P, de Leval X, Delarge J, Masereel B. Evaluation d'une nouvelle sulfonylcyanoguanidine en tant qu'antagoniste du thromboxane A2. Dans Abstract book - XIIIèmes Journées franco-belges de pharmacochimie. 1999

Somers F, De Tullio P, Boverie S, Dogne J-M, Antoine M-H, Lebrun P et al. New 3-alkylamino-4H-1, 2,4-benzothiadiazine 1, 1-dioxides as putative KATP channel openers: design, synthesis and pharmacological evaluation. Fundamental and Clinical Pharmacology. 1999;13.

1998

Masereel B, De Tullio P, Dogne J-M, Lacan F, Pirotte B, Pochet L et al. Design of new potential hypoglycemic drugs. Journal de Pharmacie de Belgique. 1998;53.

Masereel B, Ouedraogo R, Dogne J-M, Antoine M-H, De Tullio P, Pirotte B et al. Design, synthesis and pharmacology of sulfonylcyanoguanidines and sulfonamidonitroethylenes as bioisosteres of hypoglycemic sulfonylureas. Journal de Pharmacie de Belgique. 1998;53.

1997

Masereel B, Dogné JM, Damas J, Nuhrich A, Varache-Lembège M, Fontaine J et al. Pharmacomodulation of torasemide led to original diuretic, neuroproptective anticonvulsant and antithrombotic drugs. Journal de Pharmacie de Belgique. 1997 juil. 1;52(4):157-158.

Masereel B, Dogné J-M, Nuhrich A, Varache-Lembège M, Fontaine J, Pochet L et al. Pharmacomodulation studies of torasemide led to original diuretic, neuroprotective, anticonvulsant and antithrombotic drugs. Journal de Pharmacie de Belgique. 1997;52:157-158.

Masereel B, Ouedraogo RB, Dogné J-M, Antoine MH, De Tullio P, Pirotte B et al. Synthesis and biological evaluation of sulfonylcyanoguanidines and sulfonamidonitroethylenes as bioisosteres of hypoglycemic sulfonylureas. European Journal of Medicinal Chemistry. 1997;32(5):453-456.

1996

Masereel B, Lambert DM, Dogne J-M, de Tullio P, Pirotte B, Pochet L et al. BM 34, an anticonvulsivantsulfonylurea with a phenytoin-like profile. J. Pharm. Belg. 1996;51((1)):115.

Masereel B, Lebrun P, Dogné J-M, de Tullio P, Pirotte B, Pochet L et al. First synthesis of 4-substituted-benzenesulfonylcyanoguanidines. Tetrahedron Letters. 1996;37:7253-7254.

Projects

Memberships

Other Relevant Information


personal information jean-michel dogné · curriculum vitae personal information jean-michel dogné...

Documents